S10001-à effacer(NCT00403767) -NCT00403767.pdf
S10002-rivaroxaban japan phase 3 DOUBLON -NCT00494871.pdf
S10003-ATLAS ACS 2 - TIMI 51 (2.5mg) 2011-NCT00809965.pdf
S10004-MAGELLAN 2011-NCT00571649.pdf
S10005-Einstein-DVT Evaluation 2010-NCT00440193.pdf
S10006-Einstein-PE Evaluation 2012-NCT00439777.pdf
S10009-Astrup (NN8022-1807 ) 2009-NCT00422058.pdf
S10010-OB 301 (mid-dose) 0.pdf
S10011-BLOSSOM (10mg bid) 2009-NCT00603902.pdf
S10012-OB 302 (low-dose) 0.pdf
S10014-STAMINA (Amoxicillin) 2002.pdf
S10015-ARBITER-HALTS 6 2010.pdf
S10019-Borer (CL2-009) 5mg 2003.pdf
S10051-Oxford Niaspan Study 2009-NCT00232531.pdf
S10052-GOPCABE -NCT00719667.pdf
S10053-PHS (diabetics sub group) 1989.pdf
S10054-ETDRS à effacer 1992.pdf
S10055-PPP (diabetics sub group) 2003.pdf
S10056-WHS (diabetics sub group) 2005.pdf
S10059-ARBITER 6-HALTS (niacin vs ezetimibe) 2009-NCT00397657.pdf
S10062-REDEEM 2009-NCT00621855.pdf
S10067-NIA DOUBLON avec Oxford Niaspan Study, 2009 .pdf
S10068-FAIR-HF (Anker) 2009.pdf
S10073-HeartMate II 2009-NCT00121485.pdf
S10076-OCTOPUS (idem octostent) 2009.pdf
S10077-CLARITY-TIMI 28 2005.pdf
S10078-RE-COVER 2009-NCT00291330.pdf
S10083-SCOUT 2010-NCT00234832.pdf
S10102-EINSTEIN-extension 2009-NCT00439725.pdf
S10103-PROTECT 2009-NCT00351390.pdf
S10106-RABBIT -NCT00206856.pdf
S10107-BATTLESCARRED 2009-ANZCTR12605000735651.pdf
S10108-STARBRITE 2007-NCT00484770.pdf
S10110-INSTEAD 2009-NCT00525356.pdf
S10112-DORADO 2009-NCT00330369.pdf
S10115-INNOVATE -NCT00751231.pdf
S10153-NAPLES (Tavano) 2009.pdf
S10157-VanGogh PE 2007-NCT00062803.pdf
S10158-Aschner 2006-NCT00087516.pdf
S10159-Goldstein 2007-NCT00103857.pdf
S10161-Nonaka 2008-NCT00371007.pdf
S10164-Goldstein (sit vs met) 2007.pdf
S10166-Charbonnel 2006-NCT0086515.pdf
S10167-Goldstein (sit+met vs met) 2007.pdf
S10169-Nauck 2007-NCT00094770.pdf
S10170-Rosenstock (sit on top pio vs pbo) 2006-NCT00086502.pdf
S10172-Dejager [1] 2007-NCT00099905.pdf
S10174-Pi-Sunyer 2007-NCT00120536.pdf
S10177-Scherbaum [2] 2008-NCT00101712.pdf
S10180-Schweizer 2007-NCT00099866.pdf
S10182-Bolli 2008-NCT00237237.pdf
S10183-Bosi 2007-NCT00099892.pdf
S10184-Fonseca 2007-NCT00099931.pdf
S10185-Garber 2007-NCT00099853.pdf
S10187-Madsbad (vs Glimepiride) 2004.pdf
S10189-Seino 2008-NCT00154414.pdf
S10191-LEAD-3 mono 1.2mg (Garber) 2009-NCT00294723.pdf
S10192-LEAD-2 (Nauck) (1.2mg vs placebo) 2009-NCT00318461.pdf
S10193-LEAD-1 SU (1.2 mg vs placebo) 2009-NCT00318422.pdf
S10194-LEAD-4 (1.2mg) 2009-NCT00333151.pdf
S10195-LEAD-5 (vs placebo) 2009-NCT00331851.pdf
S10196-Davis 2007-NCT00099333.pdf
S10197-Barnett 2007-NCT00099619.pdf
S10198-Nauck 2007-NCT00082407.pdf
S10204-Kadowaki (trial 8683) 2009.pdf
S10206-Kim 2007-NCT00103935.pdf
S10207-Moretto (DOUBLONS avec druker) 2008-NCT00381342.pdf
S10208-Madsbad (vs placebo) 2004.pdf
S10209-LEAD-2 (Nauck) (1.2 mg vs glimepiride) 2009-NCT00318461.pdf
S10210-LEAD-5 (vs Glargine) 2009-NCT00331851.pdf
S10313-VTACH 2009-NCT00919373.pdf
S10315-SMASH-VT 2007-ISRCTN62488166.pdf
S10317-ASTRONOMER 2010-ISRCTN 32424163.pdf
S10318-SEAS 2008-NCT00092677.pdf
S10326-SPIRIT III (small vessel subgroup) 2009.pdf
S10328-AMPLIFY 2013-NCT00643201.pdf
S10329-AMPLIFY-EXT 2.5mg 2012-NCT00633893.pdf
S10330-ADOPT doublon autre MA 2011-NCT00457002.pdf
S10331-ADVANCE 1 (Lassen) DOUBLON 2009-NCT00371683.pdf
S10332-ADVANCE 3 2010-NCT00423319.pdf
S10333-ADVANCE 2 2010-NCT00452530.pdf
S10334-CV185-027 -NCT00320255.pdf
S10335-PLATO invasive subgroup 2010.pdf
S10338-APPRAISE 2 2011-NCT00831441.pdf
S10339-ARISTOTLE 2011-NCT00412984.pdf
S10340-AVERROES 2011-NCT00496769.pdf
S10341-phase 2 apixaban 0-NCT00787150.pdf
S10345-CALISTO 2010-NCT00443053.pdf
S10348-CABANA -NCT00911508)..pdf
S10352-ACCORD lipid 2010-NCT00000620.pdf
S10353-ACCORD blood pressure 2010-NCT00000620.pdf
S10355-RACE II 2010-NCT00392613.pdf
S10356-phase 2 betrixaban Ezekowitz -NCT00742859.pdf
S10364-CAMELOT (amlodipine vs enalapril) 2004.pdf
S10369-DECLARE-DIABETES 2010.pdf
S10370- RE-LY 150mg (2nd prevention subgroup) .pdf
S10371- RE-LY 110mg (2nd prevention subgroup) 2010.pdf
S10372-MICHELANGELO OASIS-6 2006-NCT00064428.pdf
S10377-FONDACAST -NCT00843492.pdf
S10378-NCT00333021 -NCT00333021.pdf
S10382-SWITCH III -NCT00464087.pdf
S10385-NCT00320398 0-NCT00320398.pdf
S10389-NAVIGATOR valsartan 2010-NCT00097786.pdf
S10391-NAVIGATOR nateglinide 2010-NCT00097786.pdf
S10400-Hot cafe (rate vs rythm control) 2004.pdf
S10401-RACE (rate vs rythm control) 2002.pdf
S10402-STAF (rate vs rythm control) 2003.pdf
S10403-AFFIRM (rate vs rythm control) 2002-NCT00000556.pdf
S10404-PIAF (rate vs rythm control) 2000.pdf
S10405-AF-CHF (rate vs rythm control) 2002-NCT00597077.pdf
S10407-EXPLORE-Xa DOUBLON 2010-NCT00742859.pdf
S10409-DES-LATE 2010-NCT00484926.pdf
S10411-DES-LATE 2010-NCT00484926.pdf
S10415-GRAVITAS 2011-NCT00645918.pdf
S10417-ARTIC (extended dual antiplatelet) 0-NCT00827411.pdf
S10418-PLATINUM 2011-NCT00823212.pdf
S10419-VA CABG 2010-NCT00054847.pdf
S10425-Gaudino (RITA) 2005.pdf
S10442-Clarke-Pearson I 1984.pdf
S10443-Clarke-Pearson II 1984.pdf
S10451-Lieberman (A) 1994.pdf
S10456-Stannard (vs UFH+asp) 1996.pdf
S10460-Kalodiki (GCS+LMWH vs LMWH) 1996.pdf
S10470-Clarke Pearson 1993.pdf
S10473-Hansberry (vs UFH) 1991.pdf
S10479-McKenna (vs aspirin) 1980.pdf
S10498-Turpie (IPD or GCS) 1989.pdf
S10500-Rasmussen (GCS vs UFH) 1998.pdf
S10502-Hansberry (vs UFH) 1991.pdf
S10520-TROPHY 2006-NCT00227318.pdf
S10522-KANT (14 days) 2008.pdf
S10584-D-KAf (Selby) 2007-NCT00187408.pdf
S10585-Handley (low dose) 1972.pdf
S10596-Bergmann and Neuhart 1996.pdf
S10603-British Bifurcation Coronary Study DOUBLON 2010.pdf
S10610-DIRECT-Carotid (Shai) 2010.pdf
S10611-DeFronzo 2009-NCT00121667.pdf
S10612-Ferrannini 2009-NCT00106340.pdf
S10614-Nauck 2009-NCT00286442.pdf
S10628-LEAD-2 (Nauck) Sulf vs pbo 2009-NCT00318461.pdf
S10629-LEAD-2 (Nauck) (vs GLP-1 analog) 2009.pdf
S10651-ARMYDA-4 RELOAD 2010.pdf
S10653-Pratley 1.2mg 2010-NCT00700817.pdf
S10654-LEADER 2016-NCT01179048.pdf
S10730-BBC ONE 2008-NCT00351260.pdf
S10738-LIFE (diabetic subgroup) 2002.pdf
S10739-ALLHAT (lisi vs chlor, diabetic subgroup) 2002.pdf
S10740-ALLHAT (amlodipine vs chlor, diabetic subgroup) 2002.pdf
S10741-STOP-2 (ACEI vs CCB) (diabetic subgroup) 2000.pdf
S10773-Rodriguez-Moctezuma 2004.pdf
S10783-ACCORD lipid (DOUBLON ) 2010.pdf
S10792-UMPIRE -NCT01057537.pdf
S10793-GAP -ACTRN12608000583347.pdf
S10794-IMPACT -ACTRN12606000067572.pdf
S10795-TIPS 2009-NCT00443794.pdf
S10796-NCT00567307 -NCT00567307.pdf
S10797-NCT00603590 -NCT00603590.pdf
S10804-RESOLUTE All comers 2010-NCT00617084.).pdf
S10834-Mark (Linxian) 1996.pdf
S10838-SYNTAX (unprotected left main sub group) 2009.pdf
S10839-SCANDSTENT (subgroup) 2006.pdf
S10840-SPEED (Phase B) 2000.pdf
S10841-SPEED (Phase B) importé 2000.pdf
S10842-SPEED (Phase A) importé 2000.pdf
S10843-SURVIVE 2007-NCT00348504.pdf
S10853-Finnish Mental Hospital (Turpeinen) 1979.pdf
S10865-Madjlessi-Simon 1995.pdf
S10867-Donaldson (nifedipine) 1993.pdf
S10868-IMAGE (Savonitto) 1996.pdf
S10878-Ruzyllo (CL3-023) 15mg 2007.pdf
S10879-INITIATIVE (CL3-017, Tardif) 20mg 2005.pdf
S10880-BEAUTIFUL 2008-NCT00143507.pdf
S10881-ASSOCIATE (Tardif) 2009-NCT00202566.pdf
S10884-phase II 10mg importé 0.pdf
S10885-phase II 15mg importé 0.pdf
S10886-Borer (CL2-009) 10mg 2003.pdf
S10887-Borer (CL2-009) 20mg 2003.pdf
S10889-ASSOCIATE (Tardif) 2009-NCT00202566.pdf
S10892-INITIATIVE (Tardif) 20mg 2005.pdf
S10893-INITIATIVE (CL3-017, Tardif) 15mg 2005.pdf
S10896-Ruzyllo (CL3-023) 20mg 2007.pdf
S10897-CANOE 2010-NCT00116932.pdf
S10943-INVEST (CAD subgroup) 2003.pdf
S10944-ALLHAT (CAD sub group) 2006.pdf
S10945-JMIC-B (CAD subgroup) 2004.pdf
S10951-Hauf-Zachariou 1997.pdf
S10967-TIBBS (von Arnim) 1995.pdf
S10973-Alderman A EFFACER .pdf
S10985-van de Ven à effacer 0.pdf
S10986-IMAGE (Savonitto) 1996.pdf
S10994-Nadazdin SANS REF 1994.pdf
S11015-Bowles REF MANQUANTE 1981.pdf
S11016-Parker SANS ref 1986.pdf
S11019-Catipovic-Veselica 1993.pdf
S11037-Steffensen (ass vs B-) 1993.pdf
S11038-Humen (ass 240 mg) 1991.pdf
S11040-Kawanishi (ass) 1992.pdf
S11041-Lynch (high dose) 1980.pdf
S11042-Friedensohn (ass) 0.pdf
S11056-Wieshammer (ass) 1991.pdf
S11058-### Miller (ass) 1976.pdf
S11060-ROADMAP 2010-NCT00185159.pdf
S11061-ORIENT -NCT00141453.pdf
S11062-Parameshwar (ass) 1993.pdf
S11066-Steffensen (ass) BOUBLON 1993.pdf
S11088-Schneider (vs PBO) 1988.pdf
S11090-Waysbort (ass) 1991.pdf
S11091-Krepp (ass) à effacer 1991.pdf
S11095-AMIHOT II 2000-NCT00175058.pdf
S11113-RE-NOVATE 2 0-NCT00657150.pdf
S11138-CLOSURE I 2010-NCT00201461.pdf
S11139-RESPECT PFO -NCT00465270.pdf
S11140-PC-Trial -NCT00166257.pdf
S11141-REDUCE -NCT00738894.pdf
S11143-CryptoCard -NCT01018355.pdf
S11144-RAN080 (vs atenolol) 2005.pdf
S11179-IMAGE (Savonitto) (ass) 1996.pdf
S11185-De Buitler (atenolol) 1984.pdf
S11186-de Buitleir à effacer 1984.pdf
S11192-Davies (CASIS) 1995.pdf
S11194-Siu (Nifedipine) 1993.pdf
S11200-Eteiba (Ismo retard) 1991.pdf
S11205-SATURN -NCT00620542.pdf
S11206-Bailey (MB102014) 2010-NCT00528879.pdf
S11207-DURATION-3 (Diamant) 2010-NCT00641056.pdf
S11209-Akhras à effacer 1990.pdf
S11212-Crake (nifedipine) 1987.pdf
S11215-Strauss DOUBLON 1984.pdf
S11218-Crake (nifedipine SR) 1987.pdf
S11221-ACCORD (sub group, Eye study) 2010-NCT00000620.pdf
S11222-ACCORD lipid (subgroup Eye study) 2010-NCT00000620.pdf
S11224-O'Keefe (10mg) 1987.pdf
S11225-Donaldson (nisoldipine) 1993.pdf
S11232-Humen (ass 360 mg) 1991.pdf
S11234-TRIMAG (Szwed) 2001.pdf
S11235-TIBET (Fox) nifedipine 1996.pdf
S11237-TRAFFIC (Emanuelsson) 1999.pdf
S11238-WHS vitamin E 2005-NCT00000479.pdf
S11239-BLOOM 2010-NCT00395135.pdf
S11241-HOPE renal insufficiency subgroup 2004.pdf
S11244-ATBC 2nd prev subgroup (vitamin E) 1998.pdf
S11250-ALLHAT (women subgroup) 2002.pdf
S11251-ASCOT (women subgroup) 2003.pdf
S11252-MEGA (women subgroup) 2006.pdf
S11253-HPS (women subgroup) 2002.pdf
S11254-JUPITER (women subgroup) 2008.pdf
S11281-Crake (pooling) 1987.pdf
S11282-Humen (pooling) 1991.pdf
S11283-O'Keefe (pooling) 1987.pdf
S11284-Toal (pooling) 1995.pdf
S11285-OPTIMA 2009-ISRCTN80874637.pdf
S11294-ACCOMPLISH (diabetic subgroup) 2010-NCT00170950.pdf
S11296-HDFP (diabetic subgroup) 1986.pdf
S11297-PART2 (diabetic subgroup) 2000.pdf
S11298-PROGRESS (diabetic subgroup) 2001.pdf
S11299-SCAT (diabetic subgroup) 2000.pdf
S11300-NICOLE (diabetic subgroup) 2001.pdf
S11301-PREVENT (diabetic subgroup) 2000.pdf
S11302-SCOPE (diabetic subgroup) 2003.pdf
S11303-AASK (diabetic subgroup) 2002.pdf
S11304-ANBP2 (diabetic subgroup) 2003.pdf
S11305-CONVINCE (diabetic subgroups) 2003.pdf
S11306-ELSA (diabetic subgroup) 2002.pdf
S11307-NICS-EH (diabetic subgroup) 1999.pdf
S11308-VHAS (diabetic subgroup) 1995.pdf
S11310-JMIC-B (diabetic subgroup) 2004.pdf
S11313-Rea 2010-NCT00219687.pdf
S11314-Svensson 2010-CT20080012.pdf
S11316-Hallstrom + preliminary study .pdf
S11318-FAVORIT -NCT00064753.pdf
S11319-CSPPT 2015-NCT00794885.pdf
S11320-SU.FOL.OM3 -ISRCTN41926726.pdf
S11321-DURATION-2 (Bergenstal) (vs sitagliptin) 2010-NCT00637273.pdf
S11322-DURATION-3 (copie de 11207) 2010.pdf
S11323-DURATION-2 (Bergenstal) (vs pioglitazone) 2010-NCT00637273.pdf
S11332-ASSOCIATE (symptomatic subgroup) 0.pdf
S11333-BEAUTIFUL (angina subgroup) .pdf
S11336-TIBET (ass vs BB or CaB) 1996.pdf
S11337-EXCLAIM 2010-NCT00077753.pdf
S11356-ATBC 2nd prev subgroup (b carotene) 1998.pdf
S11365-Soya bean (DOUBLON, A EFFACER) 0.pdf
S11366-Kurnanyika (A DEPLACER) 0.pdf
S11368-Hypertension Prevention Trial DOUBLON A EFFACER .pdf
S11387-ESPRIT-UK DOUBLON A EFFACER .pdf
S11391-WISDOM 2007-ISRCTN63718836.pdf
S11392-ERA (estrogen plus medroxyprogesterone) 2000-NCT00000549.pdf
S11393-WELL-HART (estrogen-progestin) 2003-NCT00000559.pdf
S11394-PARTNER 2010-NCT00530894.pdf
S11398-ISAR TEST 5 -NCT00598533.pdf
S11400-BIOFREEDOM -NCT01172119.pdf
S11402-Schulman (NHLBI) (estrogen-progestogen) 2002-NCT00000601.pdf
S11409-DEFINE 2010-NCT00685776.pdf
S11412-ALPHA OMEGA (EPA DHA) 2010-NCT00127452.pdf
S11414-ALPHA OMEGA (ALA) 2010-NCT00127452.pdf
S11415-INNOVATE PCI -NCT00751231.pdf
S11420-CURRENT-OASIS 7 clopidogrel PCI subgroup 2010-NCT00335452.pdf
S11421-ART 2010-ISRCTN46552265.pdf
S11449-TRITOM TIMI 38 (PCI subgroup) 2009.pdf
S11450-ISAR-TEST 4 (EES vs SES) .pdf
S11451-ESSENCE diabetes -NCT00997763.pdf
S11453-OPAL-2 -NCT00938730.pdf
S11454-phase 2 YM150 0-NCT00448214.pdf
S11455-phase 2 edoxaban 0-NCT00829933.pdf
S11456-NCT00806624 0-NCT00806624.pdf
S11458-phase 2 edoxaban 0-NCT00806624.pdf
S11459-Lip (phase 2 AZD0837) 2009-NCT00684307.pdf
S11460-phase 2 AZD0837 0-NCT00623779.pdf
S11461-phase 2 dabigatran 0-NCT01136408.pdf
S11462-ADDITION 2010-NCT00237549.pdf
S11721-Rischio and Prevenzione study DOUBLON .pdf
S11739-PROTECT 2010-NCT00328692.pdf
S11787-Pokushalov (DOUBLON DIB) 2010.pdf
S11807-PALLAS 2011-NCT01151137.pdf
S11808-ARTEMIS AF -NCT01199081.pdf
S11811-BLOOM-DM (10mg bid) -NCT00603291.pdf
S11812-CONQUER (mid-dose) (OB 303) -NCT00553787.pdf
S11813-RAFT 2010-NCT00251251.pdf
S11816-BASKET-PROVE (SES) 2010-ISRCTN72444640.pdf
S11817-BASKET-PROVE (EES) 2010-ISRCTN72444640.pdf
S11818-Verifrenchy -NCT00753753.pdf
S11822-REVEAL -NCT00378352.pdf
S11823-REVIVAL-3 -NCT00390832.pdf
S11825-TIM-HF -NCT00543881.pdf
S11826-REVEAL HPS-3 TIMI-55 -NCT01252953.pdf
S11827-APPRAISE japan -NCT00852397.pdf
S11832-CLGB 9840 (Seidman) 2008.pdf
S11839-E2100 (Miller) 2007-NCT00028990.pdf
S11840-AVADO (Miles) 15mg 2009.pdf
S11841-RIBBON-I (Robert) on top capecitabine 2009.pdf
S11842-RIBBON-I (Robert) on top Tax or anthra 2009.pdf
S11843-AVF2119g (Miller) cape 2005.pdf
S11845-GeparQuattro 2010-NCT00288002.pdf
S11847-Joensuu 2009-NCT00114816.pdf
S11848-Muss 2009-NCT00024102.pdf
S11851-EORTC 10001 (Pajk) 2008.pdf
S11854-GEPARTRIO pilot 2005.pdf
S11870-STARS J-V 0-NCT01181167.pdf
S11871-GetGoal-M-As 0-NCT01169779.pdf
S11872-ELIXA (EFC11319) 0-NCT01147250.pdf
S11873-GetGoal Duo1 0-NCT00975286.pdf
S11874-EFC10780 2010-NCT00976937.pdf
S11876-RESTORE 0-NCT00931372.pdf
S11877-PDY10931 0-NCT01175473.pdf
S11878-BP21844 0-NCT00811460.pdf
S11879-BC21893 0-NCT00909597.pdf
S11880-NC25113 0-NCT01018173.pdf
S11881-BC21625 0-NCT00717457.pdf
S11882-BC22092 0-NCT00823992.pdf
S11883-BC20750 0-NCT00744926.pdf
S11884-BC21713 (vs placebo) 0-NCT00754988.pdf
S11885-BC20963 0-NCT00744367.pdf
S11886-ZC22565 0-NCT01051011.pdf
S11887-BC20965 0-NCT00755287.pdf
S11888-LEAD-6 2009-NCT00518882.pdf
S11889-SU.FOL.OM3 2010-ISRCTN41926726.pdf
S11951-phase 2 (O'Shaughnessy) 2010-NCT00540358.pdf
S11952-APROPOS à effacer 0.pdf
S11981-Study 201 (Goldberg) 1996.pdf
S12007-Marre (ass) (ass vs glyburide) 2002.pdf
S12008-Blonde (vs metformin) 2002.pdf
S12010-Bolinder 2012-NCT00855166.pdf
S12011-Ferrannini (MB102013) 2010-NCT00528372.pdf
S12012-Wilding (MB102009) 2009-NCT00357370.pdf
S12013-add on to Glimepiride .pdf
S12014-Nauck (vs glipizide) -NCT00660907.pdf
S12015-Phase 2b dose-ranging study .pdf
S12016-Taskinen 0-NCT00601250.pdf
S12017-Lewin 2010-NCT00819091.pdf
S12018-Owens 0-NCT00602472.pdf
S12019-Del Prato 0-NCT00621140.pdf
S12048-TRA-2P TIMI 50 2012-NCT00526474.pdf
S12051-Buse 2011-NCT00765817.pdf
S12052-CAROLINA 2012-NCT01243424.pdf
S12053-linagliptine 1218.52 0-NCT00915772.pdf
S12054-linagliptin 1218.61 0-NCT00996658.pdf
S12055-linagliptin 1218.65 0-NCT01215097.pdf
S12056-linagliptin 1218.62 0-NCT01012037.pdf
S12057-linagliptine 1218.50 0-NCT00740051.pdf
S12059-A EFFACER 0-NCT00309608.pdf
S12060-linagliptin1218.5 0-NCT00328172.pdf
S12062-Gallwitz 2012-NCT00622284.pdf
S12063-linagliptin 1264.3 0-NCT01183013.pdf
S12065-linagliptin 1218.46 0-NCT00798161.pdf
S12066-CoreValve US pivotal trial -NCT01240902.pdf
S12067-PARTNER cohort A 2011-NCT00530894.pdf
S12073-Charpentier (301F) .pdf
S12089-RE-COVER II 2011-NCT00680186.pdf
S12090-RE-MEDY 2011-NCT00329238.pdf
S12091-RE-SONATE 2011-NCT00558259.pdf
S12092-Edoxaban Hokusai VTE 2013-NCT00986154.pdf
S12093-RELY - ABLE -NCT00808067.pdf
S12146-AVADO (Miles) all group together 2010.pdf
S12147-RIBBON-2 (Brufsky) 2009.pdf
S12240-ROCKET J -NCT00494871.pdf
S12241-GetGoal-X 0-NCT00707031.pdf
S12267-French Epirubicin Study 1988.pdf
S12269-EORTC 10808 (Engelsman) 1991.pdf
S12271-ECOG E3186 (Sledge) 2000.pdf
S12272-Ross A EFFACER 1985.pdf
S12299-Nicholls 2011-NCT01058018.pdf
S12303-Van Gogh (subgroup) 2011.pdf
S12309-Lead-3 (Bode) A EFFACER 2010.pdf
S12310-Hermansen (LEAD 2) A EFFACER 2010.pdf
S12311-LEAD-6 ext (Buse) 2010-NCT00518882.pdf
S12312-Seino 2010-NCT00393718.pdf
S12314-Astrup 2009-NCT00422058.pdf
S12316-Nauck ANALYSE CONJOINTE 2009.pdf
S12321-Vilsbøll Wolpert DOUBLONS A EFFACER 2007-NCT00154401.pdf
S12322-Nauck (LI+MET vs MET) 2006.pdf
S12325-Nauck (LI vs MET) 2006.pdf
S12326-LEAD 3 extension 0-NCT00853359.pdf
S12327-H8O-MC-GWDE 0-NCT01029886.pdf
S12328-HARMONY 7 (114179) 0-NCT01128894.pdf
S12329-NN2211-3533 0-NCT00761540.pdf
S12330-LIBRA 0-NCT01270789.pdf
S12331-NN2211-1800 0-NCT00943501.pdf
S12334-EAGLE 0-NCT01117350.pdf
S12335-NCT00978393 0-NCT00978393.pdf
S12336-LEAD-2 (vs MET) A VERIFIER 2009-NCT00318461.pdf
S12337-NN2211-1571 (Vilsbøll) 2007-NCT00154401.pdf
S12339-NN2211-1799 0-NCT00620282.pdf
S12340-NN2211-1796 0-NCT00614120.pdf
S12341-NN2211-1701 0-NCT00395746.pdf
S12342-NCT01234649 0-NCT01234649.pdf
S12343-NN2211-3534 0-NCT00993304.pdf
S12344-NN2211-3619 0-NCT01206101.pdf
S12345-NN8022-1923 0-NCT00781937.pdf
S12346-NN8022-1922 0-NCT01272232.pdf
S12347-MK-0431-403 0-NCT01296412.pdf
S12388-Gao 2009-NCT00324363.pdf
S12419-Ogihara 2010-NCT00151229.pdf
S12433-TAC-HFT 2014-NCT00768066.pdf
S12472-PROTECT 2011-NCT00182143.pdf
S12473-STARS E-3 0-NCT01181102.pdf
S12474-Takeshi Fuji 0-NCT01203098.pdf
S12475-DU176b-B-J302 0-NCT01181102.pdf
S12476-DU176b-B-J303 0-NCT01181141.pdf
S12477-DU176b-B-J304 0-NCT01181167.pdf
S12478-DU176b-04 0-NCT01203072.pdf
S12484-DECLARE-LONG II 2011.pdf
S12486-STICH (vs med) 2011-NCT00023595.pdf
S12487-PRECOMBAT 2011-NCT00422968.pdf
S12488-ISAR-CABG 2011-NCT00611910.pdf
S12489-OSCAR 2011-NCT00134160.pdf
S12490-NAGOYA HEART -NCT00129233.pdf
S12491-EXCELLENT 2011-NCT00698607.pdf
S12492-Camporese = KANT DOUBLON 2008.pdf
S12505-NAGOYA HEART 2011-NCT00129233.pdf
S12507-SEASIDE -NCT00963781.pdf
S12543-IMPACT-DCM 2014-NCT00765518.pdf
S12545-MARINE -NCT01047683.pdf
S12593-Pratley 1.8mg 2010-NCT00700817.pdf
S12624-LEAD-3 mono 1.8mg (Garber) 2009-NCT00294723.pdf
S12625-LEAD-4 (1.8mg) 2009-NCT00333151.pdf
S12626-LEAD-1 SU (1.8 mg vs placebo) 2009-NCT00318422.pdf
S12627-LEAD-1 SU (1.8 vs rosiglitazone) 2009-NCT00318422.pdf
S12628-LEAD-2 (Nauck) (1.8 mg vs glimepiride) 2009-NCT00318461.pdf
S12629-LEAD-2 (Nauck) (1.8mg vs placebo) 2009-NCT00318461.pdf
S12632-RECLOSE 2 ACS A EFFACER -NCT01231035.pdf
S12648-AVADO (Miles) 7.5mg 2010.pdf
S12711-Morgan DOUBLON A EFFACER 1978.pdf
S12714-TOHP I DOUBLON A EFFACER .pdf
S12715-TOHP II DOUBLON A EFFACER .pdf
S12716-TONE DOUBLON A EFFACER .pdf
S12718-Thaler women A EFFACER 1982.pdf
S12768-HOME 2009-NCT00375388.pdf
S12769-OTPE (Aujesky) 2011-NCT00425542.pdf
S12770-Otero 2010-NCT00214929.pdf
S12772-ADVANCE 2007-NCT00145925.pdf
S12774-ABCD normotensives 1993.pdf
S12777-EUROPA (PERSUADE substudy) 2005.pdf
S12779-ASCOT (subgroup) 2008.pdf
S12780-INVEST (subgroup) 2003.pdf
S12784-SOLVD (subgroup) 1996.pdf
S12785-CAPPP (subgroup) 2001.pdf
S12788-Komoroski (MB102007) 2009-NCT00162305.pdf
S12789-List (MB102008) 2009-NCT00263276.pdf
S12791-KOhan 0-NCT00736879.pdf
S12792-Wilding 2012-NCT00673231.pdf
S12793-Nauck 2011-NCT00660907.pdf
S12794-Kohan 0-NCT00663260.pdf
S12795-Kohan 0-NCT00643851.pdf
S12796-Strojek 2011-NCT00680745.pdf
S12797-MB102022 A EFFACER DOUBLON 0-NCT00660907.pdf
S12798-Rosenstock 2012-NCT00683878.pdf
S12799-MB102034 2016-NCT00859898.pdf
S12830-dal-OUTCOMES 2012-NCT00658515.pdf
S12845-Ruby-1 2011-NCT00994292.pdf
S12853-RESET 2011-NCT01035450.pdf
S12854-PRODIGY -NCT00611286.pdf
S12856-PRODIGY 2011-NCT00611286.pdf
S12857-REAL-LATE, ZEST-LATE 2010-NCT00484926.pdf
S12858-UGDP (Tolb or Phen) 1975.pdf
S12859-UGDP (insulin) 1982.pdf
S12862-Giles 2008-NCT00521820.pdf
S12864-SAMMPRIS 2011-NCT00576693.pdf
S12865- ROCKET (2nd prevention subgroup) 2011.pdf
S12909-D1690C00005 A EFFACEr DOUBLON -NCT00680745.pdf
S12951-UGDP phenformin 1975.pdf
S12952-UGDP tolbutamide 1975.pdf
S12954-PERISCOPE 2008-NCT00225277.pdf
S12979-ADOPT 2006-NCT00279045.pdf
S12980-TWENTE 2012-NCT01066650.pdf
S12981-ATLAS ACS 2 - TIMI 51 (5mg) 2011-NCT00809965.pdf
S13072-BOLERO-2 2011-NCT00863655.pdf
S13115-LIFENOX 2011-NCT00622648.pdf
S13125-Di Leo 2008-NCT00075270.pdf
S13130-EGF20002 -NCT00044330.pdf
S13131-EGF20008 -NCT00062686.pdf
S13133-EGF104900 -NCT00320385.pdf
S13136-EGF102580 -NCT00111787.pdf
S13178-TRA 2P TIMI 50 -NCT00526474.pdf
S13193-CASSIOPEA 2012-NCT00345618.pdf
S13247-TRA-2P TIMI 50 (no prior stroke sub group) 2012.pdf
S13248-TRA-2P TIMI 50 (MI subgroup) 2012-NCT00526474.pdf
S13249-FOCUS-CCTRN 2012-NCT00824005.pdf
S13250-FOCUS-HF 2011-NCT00203203..pdf
S13278-PEITHO -NCT00639743.pdf
S13295-CLEOPATRA 2012-NCT00567190.pdf
S13296-ATLAS ACS-TIMI 46 (5mg) 2009-NCT00402597.pdf
S13297-ATLAS ACS-TIMI 46 (2.5mg) 2009-NCT00402597.pdf
S13312-ESH-CHL-SHOT -NCT01563731.pdf
S13315-MB102035 -NCT00976495.pdf
S13316-MB102061 -NCT00984867.pdf
S13317-Cefalu 2015-NCT01031680.pdf
S13318-Leiter 2016-NCT01042977.pdf
S13319-MB102073 -NCT01137474.pdf
S13321-Schumm-Draeger 2015-NCT01217892.pdf
S13322-FAME II 2012-NCT01132495.pdf
S13325-WARFASA 2012-NCT00222677.pdf
S13326-neoSphere (Group B) 2012-NCT00545688.pdf
S13329-APHINITY (BIG 04-11) -NCT01358877.pdf
S13330-BO25126 A EFFACER 0-NCT01358877.pdf
S13331-PHEREXA 0-NCT01026142.pdf
S13332-MO27775 0-NCT01491737.pdf
S13333-TRYPHAENA 2013-NCT00976989.pdf
S13336-SAVE-HIP1 2012-NCT00697099.pdf
S13337-SAVE-KNEE 2012-NCT00718224.pdf
S13338-SAVE-HIP 2 2012-NCT00721760.pdf
S13354-Forst 2010-NCT00309608.pdf
S13440-BC22140 0-NCT01042769.pdf
S13441-BC20265 0-NCT00461058.pdf
S13442-SYNCHRONY 2009-NCT00388518.pdf
S13444-Rubin 2009-NCT00162175.pdf
S13445-Rubin 2008-NCT00095030.pdf
S13450-Goldstein 2006-NCT00280865.pdf
S13453-GALLANT 9 -NCT00242372.pdf
S13454-GALLANT 7 -NCT00251940.pdf
S13455-GALLANT 8 -NCT00251953.pdf
S13456-GALLANT 6 -NCT00214565.pdf
S13457-D6160C00028 -NCT00255541.pdf
S13458-D6160C00026 -NCT00252772.pdf
S13459-GALLANT 14 -NCT00261352.pdf
S13460-D6160C00055 -NCT00252837.pdf
S13461-D6160C00040 -NCT00229684.pdf
S13462-D6160C00029 0-NCT00214591.pdf
S13499-CONQUER (high-dose) (OB 303) 0-NCT00553787.pdf
S13500-OB 302 (high-dose) 0.pdf
S13501-OB 301 (high-dose) 0.pdf
S13535-Diamicron MR Study 2000.pdf
S13565-Garber (ass vs MET) 2003.pdf
S13767-TRA 2P TIMI 50 (MI subgroup) DOUBLON 2012-NCT00526474.pdf
S13768-IABP SHOCK II 2012-NCT00491036.pdf
S13770-GRACE - ORIGIN (glargine) 2012.pdf
S13771-GRACE - ORIGIN (n-3 fatty acid) .pdf
S13856-ADAPT DES -NCT00638794.pdf
S13861-ASPIRE 2012-ACTRN12605000004662.pdf
S13862-SCIPIO 2011-NCT00474461.pdf
S13867-POSEIDON 2012-NCT01087996.pdf
S13954-CHAMPION PHOENIX 2013-NCT01156571.pdf
S14194-PREDIMED (olive oil) 2013-ISRCTN35739639.pdf
S14195-PREDIMED (nuts) 2013-ISRCTN35739639.pdf
S1434-Hémorragie majeure 0.pdf
S14486-Risk and Prevention Study 2013-NCT00317707.).pdf
S14762-CANTATA-D 0-NCT01106677.pdf
S15343-ALECARDIO -NCT01042769.pdf
S15344-ALEPREVENT -EUDRACT201200067116.pdf
S15356-TASTE (Fröbert) 2013-NCT01093404.pdf
S15360-PIOcard -NCT00479986.pdf
S15361-DECLARE TIMI 58 -NCT01730534.pdf
S15362-EXSCEL -NCT01144338.pdf
S15364-CARMELINA -NCT01897532.pdf
S15365-TECOS 2015-NCT00790205.pdf
S15366-CANVAS -NCT01032629.pdf
S15367-NCT01018173 -NCT01018173.pdf
S15371-EMPA-REG MONO DOUBLON -NCT01177813.pdf
S15382-AMPLIFY-EXT 5mg 2012-NCT00633893.pdf
S1542-ASCOT (diabetics sub group) 2003.pdf
S15423-STABILITY -NCT00799903.pdf
S15425-VISTA-16 -NCT01130246.pdf
S15426-SOLID-TIMI 52 2014-NCT01000727.pdf
S1543-HPS (sub group) 2002.pdf
S1544-PROSPER (sub group) 2002.pdf
S1545-LIPID (sub group) 1998.pdf
S1546-CARE (sub group) 1998.pdf
S1547-WOSCOPS (sub group) 1996.pdf
S15470-RELAX-AHF 2013-NCT00520806.pdf
S15473-ALECARDIO 2014-NCT01042769.pdf
S15486-ODYSSEY Long-Term 2015-NCT01507831.pdf
S15487-ODYSSEY Alternative -NCT01709513.pdf
S15488-CHOICE II -NCT02023879.pdf
S15489- CHOICE I -NCT01926782.pdf
S15490-ODYSSEY OUTCOMES -NCT01663402.pdf
S15491-ODYSSEY MONO -NCT01644474.pdf
S15492-ODYSSEY FH 1 -NCT01623115.pdf
S15493-ODYSSEY FH 2 -NCT01709500.pdf
S15494-ODYSSEY HIGH FH -NCT01617655.pdf
S15496-ODYSSEY OPTIONS II .pdf
S15497-ODYSSEY COMBO -NCT01644175.pdf
S15498-ODYSSEY COMBO II -NCT01644188.pdf
S15499-NCT01288469 -NCT01288469.pdf
S15500-MENDEl 2 -NCT01763827.pdf
S15501-DESCARTES 2014-NCT01516879.pdf
S15509-PARADIGM-HF 2014-NCT01035255.pdf
S15511-SIGNIFY 2014-ISRCTN61576291.pdf
S15515-TH3RESA 2014-NCT01419197.pdf
S15543-PEGASUS 60mg 2015-NCT01225562.pdf
S15544-ITALIC -NCT01476020.pdf
S15546-Ikeda et al. A EFFACER .pdf
S15559-Hodi 2010-NCT00094653.pdf
S15560-Robert (Ipilimumab) 2011-NCT00324155.pdf
S15561-KEYNOTE-001 2014-NCT01295827.pdf
S15562-Hamid 2013-NCT01295827.pdf
S15564-CheckMate 067 (nivo + ipi) 2015-NCT01844505.pdf
S15566-BRIM 3 2011-NCT01006980.pdf
S15567-Larkin 2014-NCT01689519.pdf
S15568-Hauschild 2012-NCT01227889.pdf
S15569-Long 2014-NCT01584648.pdf
S15570-Flaherty 2012-NCT01072175.pdf
S15582-CheckMate 066 (Robert) 2015-NCT01721772.pdf
S15583-CheckMate 037 (Weber) 2015-NCT01721746.pdf
S15637-ACCENTUATE 2016-NCT02227784.pdf
S15642-OSLER 1 and 2 2015-NCT01854918.pdf
S15643-Mendel 1 2012-NCT01375777.pdf
S15644-LAPLACE-TIMI 57 -NCT01380730.pdf
S15645-GAUSS 1 2012-NCT01375764.pdf
S15646-RUTHERFORD-1 -NCT01375751.pdf
S15648-LAPLACE 2 2014-NCT01763866.pdf
S15649-GAUSS 2 -NCT01763905.pdf
S15650-RUTHERFORD-2 2015-NCT01763918.pdf
S15651-THOMAS 1 -NCT01849497.pdf
S15652-THOMAS 2 -NCT01879319.pdf
S15653-SPIRE-1 0-NCT01975376.pdf
S15654-SPIRE-2 0-NCT01975389.pdf
S15655-SPIRE-SI 0-NCT02135029.pdf
S15656-SPIRE-HR 0-NCT01968954.pdf
S15657-SPIRE-LDL 0-NCT01968967.pdf
S15658-SPIRE-FH 0-NCT01968980.pdf
S15659-SPIRE-LL 0-NCT02100514.pdf
S1566-CLAS 1987-NCT00000599.pdf
S15660-VITATOPS 2010-NCT00097669.pdf
S15661-FOURIER -NCT01764633.pdf
S15662-NeoPembroMel A EFFACER 0-NCT02306850.pdf
S15663-KEYNOTE-006 (every 2W) 2015-NCT01866319.pdf
S15664-KEYNOTE-054 -NCT02362594.pdf
S15665-CheckMate 057 2015-NCT01673867.pdf
S15666-PEGASUS 90mg 2015-NCT01225562.pdf
S15675-CUPID 2b 2016-NCT01643330.pdf
S15691-Keynote 042 -NCT02220894.pdf
S15692-POPLAR Phase 2 atezolizumab 2016-NCT01903993.pdf
S15695-CheckMate 153 -NCT02066636.pdf
S15696-CheckMate 026 2016-NCT02041533.pdf
S15697-CheckMate 017 2015-NCT01642004.pdf
S15698-CheckMate 238 0-NCT02388906.pdf
S15699-Ahmad Tarhini 0-NCT01274338.pdf
S15700-CA184-169 0-NCT01515189.pdf
S15701-EORTC Melanoma Group 0-NCT00636168.pdf
S15710-REALIZE 2015-NCT01524289.pdf
S15711-ELOQUENT 2 2015-NCT01239797.pdf
S15712-ENDEAVOR 0-NCT01568866.pdf
S15714-ASPIRE study 009 DOUBLON -NCT01080391.pdf
S15716-CLARION -NCT01818752.pdf
S15717-NCT01863550 -NCT01863550.pdf
S15718-GIMEMA -NCT00232934.pdf
S15719-HOVON 49 -ISRCTN90692740 .pdf
S15724-NCT01274403 -NCT01274403.pdf
S15725-VISTA -NCT00111319 .pdf
S15726-FIRST -NCT00689936 .pdf
S15727-MM-015 -NCT00405756 .pdf
S15728-MRC Myeloma IX -ISRCTN68454111 .pdf
S15731-NCT00911859 -NCT00911859 .pdf
S15732-EIA06 (NCT00602641) 0-NCT00602641.pdf
S15738-ExteNET 0-NCT00878709.pdf
S15739-EGF104535 0-NCT00281658.pdf
S15740-EGF105485 0-NCT00374322.pdf
S15741-Lisa Carey 0-NCT00770809.pdf
S15742-NCI-2009-00475 0-NCT00390455.pdf
S15743-NSABP B-41 0-NCT00486668.pdf
S15744-100151 0-NCT00078572.pdf
S15745-ICORG 11-10 0-NCT01526369.pdf
S15746-DETECT III 0-NCT01619111.pdf
S15747-111438 0-NCT00820222.pdf
S15748-112515 0-NCT00968968.pdf
S15749-114299 0-NCT01160211.pdf
S15750-114299 0-NCT01160211.pdf
S15751-NCT01160211 0-NCT01160211.pdf
S15752-CDR0000596572 0-NCT00688194.pdf
S15753-1200.75 0-NCT01125566.pdf
S15754-1200.32 0-NCT00949650.pdf
S15755-1200.34 0-NCT01121393.pdf
S15756-1200.42 0-NCT01085136.pdf
S15757-LUX-LUNG 1 0-NCT00656136.pdf
S15758-LUX-LUNG 8 0-NCT01523587.pdf
S15759-A011106 0-NCT01953588.pdf
S15760-EFECT (Chia) 0-NCT00065325.pdf
S15761-D6997L00021 3000-NCT01300351.pdf
S15762-CONFIRM (Di Leo) 2010-NCT00099437.pdf
S15763-Xu et al. 2011-NCT00327769.pdf
S15764-0021 (Osborne) 2002-NCT00635713.pdf
S15766-CDR0000349337 0-NCT00075764.pdf
S15767-FALCON 0-NCT01602380.pdf
S15768-DOUBLONS certainement 3000-NCT00253422.pdf
S15769-FUMANCE 0-NCT02383030.pdf
S15773-GO29058 0-NCT02340221.pdf
S15774-SOLAR-1 0-NCT02437318.pdf
S15777-MONALEESA-3 0-NCT02422615.pdf
S15820-Postow 2015-NCT01927419.pdf
S15867-Keynote 024 2015-NCT02142738.pdf
S15871-E4512 0-NCT02201992.pdf
S15872-A8081029 0-NCT01639001.pdf
S15873-Shaw 2013-NCT00932893.pdf
S15874-PROFILE 1014 2014-NCT01154140.pdf
S15875-ELOQUENT - 2 0-NCT01239797.pdf
S15876-ELOQUENT - 1 0-NCT01335399.pdf
S15878-PEARL 0-NCT02028507.pdf
S15879-PALOMA-4 0-NCT02297438.pdf
S15880-PALOMA-2 0-NCT01740427.pdf
S15881-PALOMA 3 2015-NCT01942135.pdf
S15882-PENELOPE-B 0-NCT01864746.pdf
S15883-CheckMate 067 (nivo vs ipi) 2015-NCT01844505.pdf
S15884-CheckMate 067 (nivo + ipi vs nivo) 2015-NCT01844505.pdf
S15885-GO29432 0-NCT02409355.pdf
S15886-IMpower 110 0-NCT02409342.pdf
S15887-OAK 2016-NCT02008227.pdf
S15888-IMpower 150 0-NCT02366143.pdf
S15889-PACIFIC 0-NCT02125461.pdf
S15890-ARCTIC 0-NCT02352948.pdf
S15891-MYSTIC 0-NCT02453282.pdf
S15892-NCT02273375 0-NCT02273375.pdf
S15893-CAURAL 0-NCT02454933.pdf
S15902-Castiglione-Gertsch 1993.pdf
S15906-Kellokumpu-Lehtinen 1987.pdf
S15920-Martin (motesanib) 2011-NCT00356681.pdf
S15924-TAnDEM (Kaufman) 2009.pdf
S15930-V-15-32 (Maruyama) 2008.pdf
S15931-INTEREST (Kim) 2008.pdf
S15940-CTONG0806 (Yang) 2013.pdf
S15941-NCIC CTG BR19 (Goss) 2013.pdf
S15943-INFORM; C-TONG 0804 2012-NCT00770588.pdf
S15945-Maemondo 2010-UMIN-CTR C000000376.pdf
S15946-IFCT-0301 study (Morère) 2010.pdf
S15947-WJTOG0203 (Takeda) 2010.pdf
S15948-WJTOG3405 (Mitsudomi) 2010.pdf
S15949-IPASS (Mok) 2009-NCT00322452.pdf
S15951-INVITE (Crinò) 2008-NCT00256711.pdf
S15952-SWOG S0023 (Kelly) 2008.pdf
S15957-ZODIAC 2014-NCT00312377.pdf
S15963-Natale 2011-NCT00364351.pdf
S15966-BR.20 (Arnold) 2007.pdf
S15970-FINDER 1 (Ohno) 2010.pdf
S15972-FINDER 2 2010-NCT00313170.pdf
S15974-FIRST (Robertson) 2010-NCT00274469.pdf
S15975-SoFEa (Johnston) combination 2012-NCT00253422.pdf
S15976-FACT (Bergh) 2012-NCT00256698.pdf
S15977-Mehta(SWOG-S0226) 2012-NCT00075764.pdf
S15982-BOLERO-3 2014-NCT01007942.pdf
S15983-HORIZON 2013-NCT00083993.pdf
S15984-BOLERO-1 -NCT00876395.pdf
S15985-ENGAGE-AF TIMI 48 Low dose 2013-NCT00781391.pdf
S16003-ODYSSEY Alternative (vs atorvastatin) 0.pdf
S16013-CLKGB 8081 (Perry) 1987.pdf
S16015-ECOG E3186 (Sledge) 2000.pdf
S16032-French Epirubicin Study Group 2000.pdf
S16040-Schwartzberg 2013-NCT00493636.pdf
S16043-BOLERO-4 -NCT01698918.pdf
S16044-BOLERO-6 (combination) -NCT01783444.pdf
S16046-BELLE-2 -NCT01610284.pdf
S16047-BELLE-3 -NCT01633060.pdf
S16048-BELLE-4 -NCT01572727.pdf
S16049-B-YOND -NCT02058381.pdf
S16052-ENCORE 301 2013-NCT00676663.pdf
S16053-NCT02115282 -NCT02115282.pdf
S16054-NCT02115594 -NCT02115594.pdf
S16055-MONALEESA-2 2016-NCT01958021.pdf
S16056-MONALEESA-7 -NCT02278120.pdf
S16057-Monarch3 -NCT02246621.pdf
S16058-SOPHIA -NCT02492711.pdf
S16059-MAIN-A -NCT02511639.pdf
S16060-NCT02311933 -NCT02311933.pdf
S16061-NCT01327781 -NCT01327781.pdf
S16062-Trial 301 (Kaufman) 2015-NCT00337103.pdf
S16063-Vahdat 2013-NCT00879086.pdf
S16064-EMBRACE (Cortes) 2011-NCT00388726.pdf
S16065-A EFFACER Twelves 2010.pdf
S16066-NCT02037529 -NCT02037529.pdf
S16067-Gradishar 2009-NCT00274456.pdf
S16068-A EFFACER DOUBLONS Phase 2 Gradishar 2012.pdf
S16069-tnAcity -NCT01881230.pdf
S16070-Roy 2008-NCT00110084.pdf
S16088-SoFEa (Johnston) fluvestrant alone 2012-NCT00253422.pdf
S16089-BOLERO-6 (alone) 0-NCT01783444.pdf
S16117-KEYNOTE-006 (every 3W) 2015-NCT01866319.pdf
S16118-EMPA-REG OUTCOME 2015-NCT01131676.pdf
S16119-EXAMINE 2013-NCT00968708.pdf
S16120-SAVOR TIMI 2013-NCT01107886.pdf
S16122-REWIND -NCT01394952.pdf
S16123-SPRINT 2015-NCT01206062.pdf
S16124-SUSTAIN 6 2016-NCT01720446.pdf
S16125-PROACTIVE -NCT00174993.pdf
S16126-CheckMate 025 2015-NCT01668784.pdf
S16127-METEOR 2015-NCT01865747.pdf
S16128-ASPIRE 2015-NCT01080391.pdf
S16137-AVOID HF -NCT01474200.pdf
S16152-CA204-009 0-NCT01478048.pdf
S16153-Tourmaline-MM1 0-NCT01564537.pdf
S16154-MC1181 0-NCT01415882.pdf
S16155-OlympiAD 2017-NCT02000622.pdf
S16156-NCT02163694 -NCT02163694.pdf
S16157-EMBRACA -NCT01945775.pdf
S16165-SPS3 2013-NCT00059306..pdf
S16196-FLEX (Pirker) 2009-NCT00148798.pdf
S16200-EUTRAC - NCT00446225.pdf
S16201-TITAN - NCT00556322.pdf
S16220-SATURN (Cappuzzo) - NCT00556712.pdf
S16225-RECORD-1 2008-NCT00410124.pdf
S16226-ARCC (Hudes) temsirolimus alone 2007-NCT00065468.pdf
S16228-Motzer 2007-NCT00083889.pdf
S16230-AXIS (Rini) 2011-NCT00678392.pdf
S16231-TARGET 2007-NCT00073307.pdf
S16233-CheckMate 214 0-NCT02231749.pdf
S16234-TIVO-1 2013-NCT01030783.pdf
S16238-VEG105192 2010-NCT00334282.pdf
S16240-Motzer 2015-NCT01136733.pdf
S16241-SWITCH -NCT00732914.pdf
S16242-RECORD 3 2014-NCT00903175.pdf
S16243-INTORSECT 2014-NCT00474786.pdf
S16244-PISCES 2014-NCT01064310.pdf
S16245-COMPARZ 2013-NCT00720941.pdf
S16246-STAR 2012-ISRCTN06473203.pdf
S16249-BEST 2015-NCT00378703.pdf
S16250-TORAVA 2011-NCT00619268.pdf
S16253-DOUBLON Escudier 2007.pdf
S16293-Keynote 010 2mg 2015-NCT01905657.pdf
S16299-Keynote 010 10mg 2015-NCT01905657.pdf
S16432-Sun 2013-NCT00391274.pdf
S16460-Scagliotti (pemetrexed vs bortezomib) 2010.pdf
S16466-1276.1 (bitherapy MET) 0-NCT01719003.pdf
S16467-1275.13 0-NCT02489968.pdf
S16468-1245.35 2015-NCT01947855.pdf
S16469-EASE-2 0-NCT02414958.pdf
S16470-1245.23 DOUBLON 0-NCT01159600.pdf
S16471-1245.22 0-NCT01984606.pdf
S16472-1275.9 0-NCT01734785.pdf
S16473-EMPA-REG OUTCOME 0-NCT01131676.pdf
S16474-Barnett 2014-NCT01164501.pdf
S16475-Tikkanen DOUBLON 2015-NCT01370005.pdf
S16476-Kovacs DOUBLON 2015-NCT01210001.pdf
S16477-Araki 2015-NCT01368081.pdf
S16478-Rosenstock (1245.49) 2014-NCT01306214.pdf
S16479-Ridderstrale 2014-NCT01167881.pdf
S16480-1245.29 0-NCT02182830.pdf
S16481-99050 0-NCT01257334.pdf
S16482-CRC2014EMPA 0-NCT02471963.pdf
S16483-1275.10 0-NCT01778049.pdf
S16484-1275.19 0-NCT02453555.pdf
S16485-DeFronzo 2015-NCT01422876.pdf
S16486-EASE-3 0-NCT02580591.pdf
S16488-DERIVE 0-NCT02413398.pdf
S16489-D1690C00017 0-NCT02725593.pdf
S16490-D1683C00005 0-NCT02681094.pdf
S16491-D1695C00001 0-NCT02582814.pdf
S16492-D5553C00003 0-NCT02229396.pdf
S16493-0431-838 0-NCT02532855.pdf
S16494-Rosenstock 2015-NCT01606007.pdf
S16495-DEPICT 1 0-NCT02268214.pdf
S16496-MB102-137 0-NCT02096705.pdf
S16497-MB102-054 0-NCT01095653.pdf
S16498-Yang 2015-NCT01095666.pdf
S16499-MB102-210 0-NCT02383238.pdf
S16500-CV181-363 0-NCT02284893.pdf
S16501-Depict 2 0-NCT02460978.pdf
S16502-Matthaei 2015-NCT01392677.pdf
S16503-DECLARE-TIMI 58 0-NCT01730534.pdf
S16504-Mathieu 2015-NCT01646320.pdf
S16505-CV181-365 0-NCT02419612.pdf
S16506-Kaku 2014-NCT01294423.pdf
S16507-NCT02592421 0-NCT02592421.pdf
S16508-CV181-369 0-NCT02551874.pdf
S16509-D1693C00002 0-NCT01257412.pdf
S16510-DAPA-GDM 0-NCT02338193.pdf
S16511-CV181-168 0-NCT01619059.pdf
S16512-D1690C00023 0-NCT02547935.pdf
S16513-EMPA-REG MONO DOUBLON 3000-NCT01177813.pdf
S16514-Lewin 2015-NCT01422876.pdf
S16515-Ferrannini 2013-NCT00789035.pdf
S16516-Haring DOUBLON 2013-NCT01159600.pdf
S16518-EMPA-REG PIO (Kovacs) 2013-NCT01210001.pdf
S16519-EMPA-REG MONO (Roden) vs placebo 2013-NCT01177813.pdf
S16520-Rosenstock 2013-NCT00749190 .pdf
S16523-Kadowaki 2015-NCT01193218.pdf
S16524-Ross 2015-e2012-000905-53.pdf
S16526-EMPA-REG MET (Haring) 2014-NCT01159600.pdf
S16527-Ferrannini 2013-NCT00881530.pdf
S16528-1276.1 (monotherapy) 0-NCT01719003.pdf
S16529-EMPA-REG MONO (Roden) vs sitagliptin 2013-NCT01177813.pdf
S16531-E7389-C086-304 0-NCT02225470.pdf
S16532-SCRI BRE 197 0-NCT01527487.pdf
S16533-2014-0857 0-NCT02263495.pdf
S16536-IRIS 2016-NCT00091949.pdf
S16540-HOPE 3 2016-NCT00468923.pdf
S16546-Vascular basis 2005.pdf
S16547-SQUIRE -NCT00981058.pdf
S16548-INSPIRE -NCT00982111.pdf
S16549-INSPIRE -NCT00982111.pdf
S16550-APEX 2016-NCT01583218.pdf
S16565-RELAX REPEAT -NCT01982292.pdf
S16566-RELAX-AHF-2 -NCT01870778.pdf
S16567-VERITAS 1 0-NCT00525707.pdf
S16568-VERITAS 2 0-NCT00524433.pdf
S16569-COMPOSE EARLY 0-NCT01064037.pdf
S16570-COMPOSE 1 0-NCT01065077.pdf
S16571-COMPOSE 2 0-NCT01067859.pdf
S16572-NCT00559650 0-NCT00559650.pdf
S16573-REACH UP 0-NCT00443690.pdf
S16574-PROTECT-2 0-NCT00354458.pdf
S16575-PROTECT-1 0-NCT00328692.pdf
S16576-7418-503 0-NCT00729222.pdf
S16577-CKI-203 0-NCT00159614.pdf
S16578-2007_806 0-NCT00652782.pdf
S16579-Debio 0614-202 0-NCT00838253.pdf
S16580-HORIZON-HF 0-NCT00616161.pdf
S16581-CVie2015002 0-NCT02617446.pdf
S16582-BALANCE 0-NCT00578695.pdf
S16583-TRUE-AHF 0-NCT01661634.pdf
S16586-CONVERT-H 0-NCT00843986.pdf
S16587-087-CL-071 0-NCT00057356.pdf
S16588-BLAST-AHF 0-NCT01966601.pdf
S16589-Reno-Defend 1 0-NCT00744341.pdf
S16590-S320.2.002 0-NCT00160134.pdf
S16591-TRIDENT-1 0-NCT00709865.pdf
S16592-POSEIDON 0-NCT00745316.pdf
S16593-05-025 0-NCT00283361.pdf
S16594-PARSiFAL 0-NCT02040233.pdf
S16595-PRONTO 0-NCT00803634.pdf
S16598-ixCELL-DCM 2016-NCT01670981.pdf
S16602-MARVEL 2011-NCT00526253 .pdf
S16603-Catheter-DCM 2014-NCT01020968.pdf
S16605-ESCAPE 0-NCT00841958.pdf
S16607-REMEDIUM 0-NCT02248532.pdf
S16608-BC-14-001-02 0-NCT02438306.pdf
S16609-CHART-1 0-NCT01768702.pdf
S16610-C CURE 2013-NCT00810238.pdf
S16611-TOPCARE-CHD 2006- NCT00289822.pdf
S16617-Vrtovec 2011-NCT00629018.pdf
S16618-Vrtovec 2013-NCT01350310.pdf
S16620-CADUCEUS 2012-NCT00893360.pdf
S16640-Checkmate 032 -NCT01928394.pdf
S16652-NEPTUNE -NCT02542293.pdf
S16653-JAVELIN Lung 200 -NCT02395172.pdf
S16654-JAVELIN Lung 100 -NCT02576574.pdf
S16655-AURA 3 -NCT02151981.pdf
S16680-NCT01082068 -NCT01082068.pdf
S16681-NCT01437566 -NCT01437566.pdf
S16682-NCT01277757 -NCT01277757.pdf
S16683-NCT02049957 -NCT02049957.pdf
S16686-NCT01709370 -NCT01709370.pdf
S16687-FINESSE -NCT02053636.pdf
S16688-NCT00958971 -NCT00958971.pdf
S16689-NCT01528345 -NCT01528345.pdf
S16690-NCT01791985 -NCT01791985.pdf
S16691-ADOPT 2011-NCT00457002.pdf
S16692-MARINER -NCT02111564.pdf
S16694-VOYAGER PAD -NCT02504216.pdf
S16696-COMPASS (rivaroxaban alone) -NCT01776424.pdf
S16697-COMPASS (rivaroxaban + aspirin) 0-NCT01776424.pdf
S16698-PARAMOUNT 2012-NCT00887588.pdf
S16700-TOPCAT 2014-NCT00094302.pdf
S16702-PARAGON-HF -NCT01920711.pdf
S16712-FIDELIO-DKD 0-NCT02540993.pdf
S16713-FIGARO-DKD 0-NCT02545049.pdf
S16715-SONAR 0-NCT01858532.pdf
S16716-CREDENCE 0-NCT02065791.pdf
S16717-VA NEPHRON-D 0-NCT00555217.pdf
S16718-EINSTEIN CHOICE (20mg) 2017-NCT02064439.pdf
S16733-NCT02614833 -NCT02614833.pdf
S16736-KEYNOTE-045 -NCT02256436.pdf
S16737-IMvigor211 -NCT02302807.pdf
S16738-IMvigor130 -NCT02807636.pdf
S16739-CheckMate 274 -NCT02632409.pdf
S16742-ASCEND-4 2017-NCT01828099.pdf
S16744-YO29449 0-NCT02838420.pdf
S16745-MO29750 0-NCT02604342.pdf
S16746-CLDK378A2303 0-NCT01828112.pdf
S16747-ALTA-1L 0-NCT02737501.pdf
S16748-B7461006 0-NCT03052608.pdf
S16749-X396-CLI-301 0-NCT02767804.pdf
S16770-IMvigor010 -NCT02450331.pdf
S16803-IMvigor210 -NCT02951767.pdf
S16824-Eribulin phase 3 (Schöffski ) 2016.pdf
S16825-Demetri 2016-NCT01343277.pdf
S16828-CR017269 -NCT01692678.pdf
S16829-phase 2 ET743-STS-201 -NCT00060944 .pdf
S16830-Spanish Group for Research on Sarcomas 2011.pdf
S16839-Ledermann 2012- NCT00753545.pdf
S16841-XXX veliparib -NCT02163694 .pdf
S16852-AMPLIFY EXT 2.5mg 2013.pdf
S16867-PADIS-PE (Couturaud) 2015-NCT00740883.pdf
S16868-Kearon LAFIT DOUBLON 1999.pdf
S16871-Van Gogh 2007-NCT00071279.pdf
S16873-DACUS (Siragusa) 2008-NCT00438230.pdf
S16874-EINSTEIN CHOICE (10mg) 2017-NCT02064439.pdf
S16876-British Thoracic Society 1992.pdf
S16877-PROLONG (Palarati) 2006-NCT00264277.pdf
S16879-DDOAT2006 -NCT00895505.pdf
S16886-CANTOS 2017-NCT01327846.pdf
S16887-AMPLIFY EXT 5mg 2013.pdf
S2093-HPS (sub group) 2002.pdf
S2225-Johnson WC (PTFE vs veine saphène ) 2000.pdf
S2236-Veterans Study Group 141 1988.pdf
S2259-Johnson WC (PTFE vs HUV) 2000.pdf
S2308-Regensteiner JG 1996.pdf
S2325-Dawson (pentoxifylline) 2000.pdf
S2345-Scandinavian study 1989.pdf
S2358-Trubestein (naftidrofuryl) 1984.pdf
S2364-Dawson (cilostazol) 2000.pdf
S2372-Dormandy Etude A 2000.pdf
S2373-Dormandy Etude B 2000.pdf
S2381-Ciprostene study 1991.pdf
S2416-Van der Stricht 1977.pdf
S2561-CARDS 2004-NCT00327418.pdf
S2564-ALLHAT 2002-NCT00000542.pdf
S2566-NHLBI (Brensike) 1984-NCT00000594.pdf
S2571-FIELD 2005-ISRCTN64783481.pdf
S2576-MARS 1993-NCT00116870.pdf
S2577-FATS 1990-NCT00000512.pdf
S2585-VA-HIT 1999-NCT00283335.pdf
S2595-Carlson (Stockholm) 1977.pdf
S2600-Veterans Ad. (Dayton) 1969.pdf
S2603-Oslo Diet Heart Study (Leren) 1966.pdf
S2608-PEACE 2004-NCT00000558.pdf
S2616-PATAF (vs coumadin low dose) 1999.pdf
S2617-AFASAK II (aspirin vs warfarin low dose) 1998.pdf
S2618-PATAF (coumadin low dose vs coumadin standard dose) 1999.pdf
S2619-AFASAK II (warfarin low dose vs warfarin standard dose) 1998.pdf
S2620-AFASAK II (warfarin low dose+aspirin vs warfarin standard dose) 1998.pdf
S2624-AFASAK II (aspirin vs warfarin standard dose) 1998.pdf
S2625-PATAF (vs coumadin standard dose) 1999.pdf
S2627-AFASAK (aspirin vs placebo) 1989.pdf
S2628-SPAF I (preliminary report) importé 1990.pdf
S2629-LASAF(aspirin vs no treatment) 1999.pdf
S2630-SPAF (aspirin,warfarin ineligible arm) 1991.pdf
S2632-AFASAK (warfarin standard dose vs control) 1989.pdf
S2633-BAATAF (warfarin vs no treatment) 1990-NCT00000517.pdf
S2634-SPAF (warfarin standard dose) 1991.pdf
S2635-SPINAF (warfarin vs placebo) 1992.pdf
S2636-SPORTIF II (ximelagatran vs warfarin standard dose) 2002.pdf
S2642-UK-TIA(high dose) 1991.pdf
S2643-UK-TIA(low dose) 1991.pdf
S2645-SIFA 1997-NCT00244426.pdf
S2648-NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose) 2004.pdf
S2650-SAFT(warfarin low dose + aspirin vs no treatment) 2003.pdf
S2652-NASPEAF (triflusal vs coumadin standard dose)) 2004.pdf
S2653-NASPEAF (triflusal+coumadin medium dose vs triflusal) 2004.pdf
S2654-AFASAK (aspirin vs warfarin standard dose) 1989.pdf
S2655-CAMELOT (enalapril) 2004.pdf
S2659-CLAAF(aspirin + clopidogrel vs warfarin standard dose) 2004.pdf
S2660-BAFTA (aspirin vs warfarin standard dose) 0.pdf
S2661-ACTIVE(aspirin + clopidogrel vs warfarin) 0.pdf
S2662-SPAF (aspirin , warfarin eligible arm) 1991.pdf
S2679-Deutsche Diabetes Dialyse Studie (4D) 2005.pdf
S315-AMIS 1980-NCT00000491.pdf
S3437-NORVIT (folic acid + B12) (Bonaa) 2006-NCT00266487.pdf
S3438-SEARCH 2007-NCT00124072.pdf
S3443-COMMIT 2005-NCT00222573.pdf
S3449-PROVE IT - TIMI 22 2004.pdf
S3462-MRC I (vs placebo) 1985.pdf
S3463-MRC I (vs diuretics) 1985.pdf
S3469-MRC old (vs placebo) 1992.pdf
S3470-MRC old (vs diuretics) 1992.pdf
S3479-INVEST 2003-NCT00133692.pdf
S3494-STOP 2 (vs diurectic or beta-blocker) 1999.pdf
S3498-STOP-2 (vs felodipine or isradipine) 1999.pdf
S3499-STOP 2 (vs conventional drugs) 1999.pdf
S3502-CASTEL (vs clonidine) 0.pdf
S3503-CASTEL (vs betablocker + diuretic) 0.pdf
S3627-SHEP 1991-NCT00000514.pdf
S3636-SYNERGY 2005-NCT00043784.pdf
S3637-RIO europe 20mg 2005.pdf
S3638-Rio-lipid 20 mg 2005.pdf
S3651-PEP hip-fracture 2000.pdf
S3680-PEP elective arthroplasty 2000.pdf
S3696-ATBC beta carotene 1994.pdf
S3697-CARET beta carotene 1996.pdf
S3698-HPS antioxidant 2002.pdf
S3699-SCP beta carotene 1990.pdf
S3701-NSCP (Green) beta carotene 1999.pdf
S3702-PHS beta carotene 1996.pdf
S3703-WHS beta carotene 1999-NCT00000479.pdf
S3714-ACME 2 (Folland) 1997.pdf
S3734-Lincoff (EPISTENT) 1999-NCT00271401.pdf
S3823-ISIS1 Collaborative Group 1986.pdf
S3831-MIAMI Trial Research Group 1985.pdf
S3860-Australian and Swedish study 1983.pdf
S3864-BHAT 1982-NCT00000492.pdf
S3871-LIT Research Group 1987.pdf
S3874-Multicentre international 1975.pdf
S3875-Norwegian Multicentre Study Group 1981.pdf
S3881-Schwartz (high risk and low risk) 1992.pdf
S3984-NSGET (efficacy trial) 2000.pdf
S3985-VMAC (24h) 2002-NCT00083772.pdf
S3988- PRISM-PLUS Low-dose+heparin 1998.pdf
S3989- PRISM-PLUS High-dose 1998.pdf
S3990- PARAGON-A Low-dose (no heparin) 1998.pdf
S3991- PARAGON-A Low-dose lamifiban + heparin 1998.pdf
S3992- PARAGON-A High-dose lamifiban (no heparin) 1998.pdf
S3993- PARAGON-A High-dose lamifiban + heparin 1998.pdf
S3994- PURSUIT low dose 1998.pdf
S3997- GUSTO-IV ACS Abciximab 24 h 2001.pdf
S3998- GUSTO-IV ACS Abciximab 48 h 2001.pdf
S4005-Schulman et al (Hopkins study) Low dose 1995.pdf
S4006-Schulman et al (Hopkins study) high dose 1995.pdf
S4008-TACTICS-TIMI 18 2001.pdf
S4010-RITA 3 2002-ISRCTN07752711r.pdf
S4025-Canadian (Aspirin + sulfinpyrazone) 1985.pdf
S4036-INVEST (Pepine) 2003-NCT00133692.pdf
S4037-COMMIT 2005-NCT00222573.pdf
S4042- CHARM-Alternative 2003.pdf
S4043- Crozier et al. 1995.pdf
S4044- Dickstein et al. 1995.pdf
S4047- Hamroff et al. 1999.pdf
S4050-Mazayev et al. (vs placebo) 1998.pdf
S4051- Mitrovic et al. 2003.pdf
S4053-Losartan Phase III International 1996.pdf
S4054-Losartan Phase III U.S. 1995.pdf
S4056-RESOLVD (candesartan alone) 1999.pdf
S4057- RESOLVD association 1999.pdf
S4063- VALIANT (valsartan alone) 2003.pdf
S4064- VALIANT (valsartan+capropril) 2003.pdf
S4066-DCCT (no retinopathy) 1993.pdf
S4068-Mazayev et al. (vs lisinopril 1998.pdf
S4080-Captopril Digoxin Multicenter Research Group 1988.pdf
S4083-Munich MHFT (Kleber) 1992.pdf
S4086-Rucinska-b (enalapril) 1991.pdf
S4088-Enalapril CHF investigators 1987.pdf
S4091-Rucinska-a (enalapril) 1991.pdf
S4094-Rucinska-c (lisinopril) 1000.pdf
S4112-Notarbartolo et al 1988.pdf
S4114-Etude Multicentrique 1989.pdf
S4117-Harenberg et al 1990.pdf
S4118-Collaborative European Multicentre 1991.pdf
S4122-Simonneau et al 1993.pdf
S4124-Lindmarker et al 1993.pdf
S4210-GRAMI (Rodriguez) 1998.pdf
S4211-Zwolle 5 (Suryapranata) 1998.pdf
S4212-stent-PAMI (Grines) 1999.pdf
S4214-PRISAM (Kawashima) 1999.pdf
S4215-STENTIM-2 (Maillard) 2000.pdf
S4216-PSSAAMI (Scheller) 2001.pdf
S4217-Stone (CADILLAC) 2002.pdf
S4221-ACES 2005-NCT00000617.pdf
S4224-Leowattana et al 2001.pdf
S4225-STAMINA (Azithromycin) 2002.pdf
S4230-Western Australia Study 2004.pdf
S4231-Viborg County Study 2002.pdf
S4232-Chichester Study, Men 1995.pdf
S4233-Chichester Study, Women 1995.pdf
S4257-British Doctor’s Trial 1988.pdf
S4258-Physicians Health Study 1989-NCT00000500.pdf
S4259-Thrombosis Prevention Trial 1998-NCT00000614.pdf
S4261-Primary Prevention Project 2001.pdf
S4289-Belardinelli et al 1999.pdf
S4291-Giannuzzi et al 1997.pdf
S4292-Hambrecht et al 1995.pdf
S4293-Kiilavuori et al 2000.pdf
S4297-Willenheimer et al 1998.pdf
S4301-CLARICOR 2006-NCT00121550.pdf
S4313-US carvedilol pooling 1996.pdf
S4333-ECG ancillary EIS 1985.pdf
S4334-CARMEN (carvedilol+enalapril) 2004.pdf
S4351-WHI low fat 2005-NCT00000611.pdf
S4355-TNT 2005-NCT00327691.pdf
S4356-IDEAL 2005-NCT00159835.pdf
S4357-LIPS (sub groups) 2002.pdf
S4367-CHARISMA 2006-NCT00050817.pdf
S4368-HOPE 2 (doublon) 2006.pdf
S4370-NORVIT (vit B6) (Bonaa) 2006-NCT00266487.pdf
S4371-NORVIT (folic acid, B12 and vit B6) (Bonaa) 2006-NCT00266487.pdf
S451-Western Washington Intravenous Trial 1988-NCT00000507.pdf
S452-German Multicenter Trial 1988.pdf
S4535-Sterner-Victorin 2004.pdf
S456-International Study Group 1990.pdf
S460-GUSTO tPA-SK Hiv 1993.pdf
S4680- VALIANT (valsartan alone) 2003.pdf
S4681- VALIANT (valsartan+capropril) 2003.pdf
S4721-ACTIVE W 2006-NCT00243178.pdf
S4737-HELVETICA (Serruys) 1995.pdf
S4775-Toohill (MCW-2) 1987.pdf
S4776-Jortay (EORTC 24771) 1990.pdf
S4777-Lewin (SHNG-85) 1997.pdf
S4778-Martin (Créteil-86) 1994.pdf
S4779-Paccagnella (GSTTC-86 ) 1994.pdf
S4780-Domenge (GETTEC neo1) 1995.pdf
S4781-Domenge (GETTEC) 2000.pdf
S4783-Tejedor (Las Palmas) 1992.pdf
S4784-Gedouin (Rennes-87) 1996.pdf
S4785-Di Blasio (Parma) 1994.pdf
S4786-Depondt (CFHNS) 1993.pdf
S4787-Volling (Cologne) 1994.pdf
S4788-Hasegawa (HNAP-02) 1996.pdf
S4790-Richard (IGR-65) 1974.pdf
S4791-Fazekas (RTOG 6801) 1980.pdf
S4793-Pearlman (Denver 77 ) 1985.pdf
S4795-Richard (EORTC 78-OCP) 1991.pdf
S4797-Schuller (SWOG 8006) 1988.pdf
S4798-Szpirglas (Pitié-81 ) 1988.pdf
S4799-Carugati (Buenos Aires ) 1988.pdf
S4800-Mazeron (Créteil-82) 1992.pdf
S4801-Brunin (HNCGIC02) 1989.pdf
S4802-Salvajoli (AC Camargo) 1992.pdf
S4814-RIO-North America 20 mg 2006-NCT00029861.pdf
S4819-RIO europe (20 vs 5 mg) 2005.pdf
S4820-RIO-North America 5mg 2006.pdf
S4821-RIO-North America (20mg vs 5mg) 2006.pdf
S4839-Deerochanawong, 2001.pdf
S4974-MEGA 2006-NCT00211705.pdf
S4975-DREAM ramipril 2006-NCT00095654.pdf
S4976-DREAM rosiglitazone 2006-NCT00095654.pdf
S4977-DREAM 2005-NCT00421330.pdf
S4978-EVAR trial 2 2005-ISRCTN55703451.pdf
S4979-EVAR trial 1 2005-ISRCTN55703451.pdf
S4986-Jaulerry Trial 2 (Curie)(HNCGIC03) 1992.pdf
S4987-Maipang (Songkla) 1995.pdf
S4996-RTOG 91-11 (I+RT vs RT alone) 2003.pdf
S5006-Veterans Affairs 1998.pdf
S5007-EORTC 24891 1996-EORTC 24891.pdf
S5024-DeCIDE (IRB 13362B, Chicago) 0-NCT00117572.pdf
S5025-National Health Research Institutes, Taiwan 0-NCT00201396.pdf
S5615-EORTC 24971 (TAX 323) 2006-NCT00003888.pdf
S5616-Posner (TAX324) 2007-NCT00273546.pdf
S5618-GORTEC 2000-01 0-NCT00169182.pdf
S5716-Hitt paclitaxel 2005.pdf
S5728-BNP-CARDS 2007-NCT00186329.pdf
S5732-COURAGE 2007-NCT00007657.pdf
S5733-EVEREST Clinical Status 2007-NCT00071331.pdf
S5734-EVEREST Outcome 2007.pdf
S5738-MERLIN TIMI 36 2007-NCT00099788.pdf
S5739-ERICA 2006-NCT00091429.pdf
S5741-ARISE 2007-NCT00066898.pdf
S5748-VALIDD 2007-NCT00170924.pdf
S5753-METEOR 2007-NCT00225589.pdf
S5754-ICTUS 2007-ISRCTN82153174.pdf
S5762-Licitra 2003-NCT00002747.pdf
S5763-Clark (Dana farber cancer Institute 83-084) 1988.pdf
S5768-Buffoli (Brescia) 1992.pdf
S5769-Merlano (INRC HN-7) 1991.pdf
S5771-Taylor (ICC-PCP) 1994.pdf
S5789-Pearlman (Denver 77 ) 1985.pdf
S5816-Merlano (INRC HN-7) 1990.pdf
S5817-Adelstein (CMGH-85) 1990.pdf
S5822-RTOG 91-11 (I+RT vs concurrent CRT) 2003.pdf
S5845-EORTC 24954 0-EORTC 24954.pdf
S588-ANBPS (Australian ) 1980.pdf
S590-MCR 35-64 (diuretics vs pbo) 1985.pdf
S595-ABCD hypertension 1998.pdf
S597-MIDAS (diabetic sub group) 1997.pdf
S607-BARI 1996-NCT00000462.pdf
S610-EAST 1994-NCT00000465.pdf
S617-SOLVD treatment 1991-NCT00000516.pdf
S619-SOLVD prevention 1992-NCT00000516.pdf
S620-Canadian study (CCSG) 1978.pdf
S623-UK-TIA high dose 1988.pdf
S641-EPISTENT à effacer doublons 1998.pdf
S642-Serruys Benestent 2 1998.pdf
S6443-Mateo à effacer 1984.pdf
S647-Serruys Benestent 1994.pdf
S6473-Floris (SR 200mg od) 1982.pdf
S6476-DIRDURANG (Frances) 200mg 1995.pdf
S6477-DIRDURANG (Frances) 300mg 1995.pdf
S6497-Bala Subramanian 1983.pdf
S6506-Strauss à supprimer 1982.pdf
S6509-Balasubramanian 1976.pdf
S6513-TAX324 (Larynx preservation subset) 2007-NCT00273546.pdf
S6538-INITIATIVE (Tardif) 15mg 2005.pdf
S6543-SISR 2007-NCT00231257.pdf
S6546-RAVEL 2002-NCT00233805.pdf
S6547-SIRIUS 2003-NCT00232765.pdf
S6548-C-SIRIUS 2004-NCT00381420.pdf
S6549-E-SIRIUS 2003-NCT00235144.pdf
S6551-TAXUS II 2003-NCT00299026.pdf
S6552-TAXUS IV 2004-NCT00292474.pdf
S6553-ASPECT 2003-NCT00196079.pdf
S6562-TAXUS V (all patients) 2005-NCT00301522.pdf
S6563-TAXUS VI 2005-NCT00297804.pdf
S6564-PASSION 2006-ISRCTN65027270.pdf
S6571-PRISON II 2006-NCT00258596.pdf
S6572-SCANDSTENT 2006-NCT00151658.pdf
S6573-TYPHOON 2006-NCT00232830.pdf
S6574-SESAMI 2007-NCT00288210.pdf
S6575-DECODE 2005-NCT00489164.pdf
S6576-SCORPIUS 2007-NCT00495898.pdf
S6577-RRISC 2006-NCT00263263.pdf
S6578-MISSION 2008-ISRCTN62825862.pdf
S6581-ISAR-DESIRE (SES vs PES) 2005.pdf
S6583-SIRTAX (Windecker) 2005.pdf
S6585-REALITY 2006-NCT00235092.pdf
S6586-ISAR-SMART 3 2006-NCT00146575.pdf
S6587-Zhang (SES vs PES) 2006.pdf
S6590-SORT OUT II 2008-NCT00388934.pdf
S6596-BASKET (vs paclitaxel) 2005.pdf
S6597-Di Lorenzo et al. 2005.pdf
S6599-Stone pooled analysis sirolimus 2007.pdf
S6600-Stone pooled analysis TAXUS studies 2007.pdf
S6601-Spaulding pooled analysis Ravel Sirius studies 2007-NCT00232765.pdf
S6608-ABSORB 0-NCT00300131.pdf
S6611-STRATEGY 2005-NCT00229515.pdf
S6615-Ravel (diabetics) 2004.pdf
S6619-SES-SMARt (diabetics) 2005.pdf
S6620-TAXUS II (diabetics) 2003.pdf
S6622-TAXUS IV (diabetics) 2005-NCT00292474.pdf
S6623-TAXUS V (diabetics) 2005.pdf
S6624-TAXUS VI (diabetics) 2005-NCT00297804.pdf
S6625-pooled SIRIUS (diabetics) 0.pdf
S6627-ISAR-CABG 0-NCT00611910.pdf
S6628-SPIRIT I 2005-NCT00180453.pdf
S6629-CRISTAL 0-NCT00323895.pdf
S6630-RES-I 2010-NCT00606333.pdf
S6631-PERSEUS Workhorse 2010-NCT00484315.pdf
S6632-DEFER-DES 0-NCT00592228.pdf
S6633-BASKET-SAVAGE 0-NCT00595647.pdf
S6634-EK-12006 0-NCT00279006.pdf
S6635-LEADERS 2008-NCT00389220.pdf
S6636-DES-ISR 0-NCT00485030.pdf
S6637-GISSOC II 2010-NCT00220558.pdf
S6638-FRE-RACE 0-NCT00130546.pdf
S6639-DIABEDES IV 0-NCT00552994.pdf
S6640-SPIRIT II 2006-NCT00180310.pdf
S6641-SYNTAX 2009-NCT00114972.pdf
S6644-Lipsia-Yukon-DM 0-NCT00368953.pdf
S6645-ENDEAVOR III 2006-NCT00217256.pdf
S6646-ENDEAVOR IV 2009-NCT00217269.pdf
S6647-Nordic Bifurcation Study 0-NCT00376571.pdf
S6648-SPIRIT IV 2010-NCT00307047.pdf
S6649-SPIRIT III 2008-NCT00180479.pdf
S6650-LEFT-MAIN-2 0-NCT00598637.pdf
S6651-VELETI 0-NCT00289835.pdf
S6652-ISAR-TEST-1 2006-NCT00140530.pdf
S6653-Leipzig 0-NCT00176397.pdf
S6654-ISAR-DESIRE-2 2010-NCT00598715.pdf
S6655-ISAR-LEFT-MAIN 2009-NCT00133237.pdf
S6656-ZoMaxx phase 2 0-NCT00140101.pdf
S6657-ZoMaxx phase 3 2007-NCT00148356.pdf
S6658-PEPCAD IV 0-NCT00462631.pdf
S6659-Nordic Bifurcation Stent Technique Study 0-NCT00292305.pdf
S6661-RESEARCH à effacer 2004.pdf
S6662-PROTECT 2012-NCT00476957.pdf
S6663-PEPCAD III 0-NCT00473499.pdf
S6664-MIDCAB Versus DES in Proximal LAD Lesions 0-NCT00299429.pdf
S6665-PRISON III 2007-NCT00428454.pdf
S6666-SORT OUT IV 2012-NCT00552877.pdf
S6667-FEMH-93005 0-NCT00190099.pdf
S6669-GENESIS Trial CP-01 0-NCT00322569.pdf
S6677-EORTC 24971 (TAX 323) 2006-NCT00003888.pdf
S6678-Posner (TAX324) 2007-NCT00273546.pdf
S6679-GORTEC 2000-01 0-NCT00169182.pdf
S6688-- Clark (Dana farber cancer Institute 83-084) 1988.pdf
S6697-Toohill (MCW-2) 1987.pdf
S6699-Lewin (SHNG-85) 1997.pdf
S6700-Paccagnella (GSTTC-86 ) 1994.pdf
S6701-Domenge (GETTEC neo1) 1995.pdf
S6702-Domenge (GETTEC) 2000.pdf
S6704-Tejedor (Las Palmas) 1992.pdf
S6705-Gedouin (Rennes-87) 1996.pdf
S6706-Di Blasio (Parma) 1994.pdf
S6707-Depondt (CFHNS) 1993.pdf
S6708-Volling (Cologne) 1994.pdf
S6709-Hasegawa (HNAP-02) 1996.pdf
S6712-Licitra 2003-NCT00002747.pdf
S6714-EORTC 24844 0-EORTC-24844.pdf
S6718-ZEST (vs SES) 2009-NCT00418067.pdf
S6719-ZEST AMI (vs PES) 2009-NCT00422565.pdf
S6722-Kirtane (pooled Taxus diabetic patients) 2008.pdf
S6723-ACCORD 2008-NCT00000620.pdf
S6725-ADVANCE 2008-NCT00145925.pdf
S6726-ADVANCE 2007-NCT00145925.pdf
S6727-RE-MOBILIZE (220mg) 2008.pdf
S6728-RE-MODEL (220mg) 2007.pdf
S6729-RE-NOVATE (220mg) 2007-NCT00168818.pdf
S6736-ISAR-REACT 3 2008-NCT00262054.pdf
S6739-STEEPLE 2006-NCT00077844.pdf
S6741-ONTARGET (telmisartan alone) 2008-NCT00153101.pdf
S6743-ONTARGET (association vs ramipril) 2008-NCT00153101.pdf
S6744-PERISCOPE 2008-NCT00225277.pdf
S6745-STRADIVARIUS 2008-NCT00124332.pdf
S6747-CRESCENDO 2010-NCT00263042.pdf
S6748-taranabant phase 3 0.pdf
S6749-IMPROVE-IT 2014-NCT00202878.pdf
S6751-JUPITER 2008-NCT00239681.pdf
S6758-TOSCA-2 2006-NCT00025766.pdf
S6786-CORONA 2007-NCT00206310.pdf
S6792-ASPECT-2 (coumadin alone) 2002.pdf
S6796-WARIS II (warfarin alone) 2002.pdf
S6813-OCTOSTENT 2003-NCT00975858.pdf
S6815-SOS 2002-NCT00475449.pdf
S6818-CARDia (PCI) 2008-ISRCTN19872154.pdf
S6819-FREEDOM 2012-NCT00086450.pdf
S6827-Mayo-B (Chesebro) 1983.pdf
S6831-VA bypass IV-B (aspirin 325 od) 1989.pdf
S6854-Dutch sulphinpyrazone 1986.pdf
S6862-Louvain sulphinpyrazone 1983.pdf
S6867-Schwartz (Toronto) 1988.pdf
S6868-White (aspirin+dipiridamol) 1991.pdf
S6874-M-HEART II (aspirin) 1995.pdf
S6887-GESIC (aspirin) 1990.pdf
S6901-Toronto dipyridamole 1987.pdf
S6904-German sulotroban 1989.pdf
S6912-OPI-504 -NCT00521820.pdf
S6920-OPI-520 -NCT00521742.pdf
S6924-OPI-506 0-NCT00494312.pdf
S6936-AVM100264 -NCT00359112.pdf
S6968-ADOPT 2006-NCT00279045.pdf
S6969-OASIS 6 2007-NCT00064428.pdf
S6971-Glucose-insulin-potassium study II 2007.pdf
S6973-Bucciarelli-Ducci 2006.pdf
S6975-A to Z 2004-NCT00251576.pdf
S6979-Costar II 2008-NCT00165035.pdf
S702-VA-HIT 1999-NCT00283335.pdf
S7039-SHEP (diabetic subgroup) 1996.pdf
S7040-Syst-Eur (diabetic subgroup) 1999.pdf
S7041-HOPE (diabetic subgroup) 2000.pdf
S7044-CAPP (diabetic subgroup) 1999.pdf
S7045-NORDIL (diabetic subgroup) 2000.pdf
S7046-INSIGHT (diabetic subgroup) 2000.pdf
S7047-STOP-2 CCB (diabetic subgroup) 2000.pdf
S7048-STOP-2 ACEI (diabetic subgroup) 2000.pdf
S7049-IDNT irbesartan 2001.pdf
S7050-IDNT amlodipine 2001.pdf
S7051-IDNT (irbesartan vs amlodipine) 2001.pdf
S7052-Coope (subgroup ) 1986.pdf
S7053-EWPHE (subgroup ) 1985.pdf
S7054-SHEP-P (subgroup ) 1989.pdf
S7055-SHEP (subgroup ) 1991.pdf
S7056-STOP (subgroup ) 1991.pdf
S7057-Syst-Eur (subgroup ) 1997.pdf
S7058-CASTEL (subgroup ) 1994.pdf
S7069-AASK (vs metoprolol) 2002.pdf
S7070-ALLHAT (vs chlorthalidone) 2002.pdf
S7073-AASK (vs amlodipine) 2002.pdf
S7075-ALLHAT (vs amlodipine) 2002.pdf
S7079-AASK (vs metoprolol) 2002.pdf
S7080-ALLHAT (CCB vs diu) 2002.pdf
S7083-IDNT (vs placebo) 2001.pdf
S7094-ACCOMPLISH 2008-NCT00170950.pdf
S7096-COMPANION (CRT vs MT) 2004.pdf
S7101-HYVET 2008-NCT00122811.pdf
S7102-ALLHAT (CCB vs ACEI) 2002.pdf
S7104-No trial available for MK-0524A 0.pdf
S7105-AASK (vs ramipril) 2002.pdf
S7109-MRC (diu vs BB) 1985.pdf
S7111-VALUE 2004-NCT00129233.pdf
S7114-IDNT (vs amlodipine) 2001.pdf
S7116-RE-MODEL (150mg) 2007.pdf
S7117-RE-NOVATE (150mg) 2007-NCT00168818.pdf
S7118-RE-MOBILIZE (150mg) 2008.pdf
S7119-BISTRO II (225mg bid) 2005.pdf
S712-No trial available for aaa 0.pdf
S7120-PENTAMAKS (Bauer) 2001.pdf
S7121-PENTHIFRA–PLUS (Eriksson) 2003.pdf
S7122-PENTHIFRA (Eriksson) 2001.pdf
S7123-PENTATHLON (Turpie) 2002.pdf
S7124-EPHESUS (Lassen) 2002.pdf
S7125-Phase II (Heit) 2001.pdf
S7126-Platinum (Colwell) 2003.pdf
S7133-Massachusetts-II 1976.pdf
S7184-TRIAS-HR 2008-ISRCTN74297220.pdf
S7185-TRIAS-High-Risk à effacer 0.pdf
S7193-EURIDIS 2007-NCT00259428.pdf
S7194-ADONIS 2007-NCT00259376.pdf
S7195-the Italian Elderly ACS study 0-NCT00510185.pdf
S7218-RE-LY (150mg) 2009-NCT00262600.pdf
S7219- Weitz (edoxaban phase 2) 0-NCT00504556.pdf
S7221-idraparinux BOREALIS-AF 0-NCT00580216.pdf
S7222-ROCKET-AF 2010-NCT00403767.pdf
S7223-AMADEUS 2008-NCT00070655.pdf
S7226-APROPOS 2.5mg 2007-NCT00097357.pdf
S7229-DRIVE 2008-NCT00338897.pdf
S7231-OASIS 5 2006-NCT00139815.pdf
S7235-Gurfinkel (LMWH+asp vs UFH+asp) 1995.pdf
S7240-Cohen (ATACS pilot) (heparin+aspirin vs asp) 1990.pdf
S7241-RISC (heparin+aspirin vs ASP) 1990.pdf
S7242-Theroux (heparin+aspirin vs PBO) 1988.pdf
S7243-Gurfinkel (UFH+aspririn vs aspirin) 1995.pdf
S7247-Leicester (Naylor) 1998.pdf
S7248-WALLSTENT (Alberts) 2001.pdf
S7249-CAVATAS-CEA 2001-ISRCTN01425573.pdf
S7250-Kentucky A (Brooks) 2001.pdf
S7256-Theroux (heparin vs PBO) 1988.pdf
S7257-RISC (heparin vs PBO) 1990.pdf
S7258-Cohen (ATACS pilot) (heparin vs asp) 1990.pdf
S7259-Gurfinkel (LMWH+asp vs asp) 1995.pdf
S7260-FRIC prolonged treatment phase (LWMH vs PBO) 1997.pdf
S7262-TRITON-TIMI 38 2007-NCT00097591.pdf
S7263-CURE PCI importé 2001.pdf
S7271-Cilazapril-Captopril Multi-centre Group 1995.pdf
S7282-Quinapril Heart Failure Trial Investigators 1993.pdf
S7284-I-PRESERVE (McMurray) 2008-NCT00095238.pdf
S729-FRISC (long term) 1996.pdf
S7293-HELAS (warfarin vs placebo) 2006.pdf
S7294-WATCH (warfarin vs aspirin) 2009-NCT00007683.pdf
S7295-Losartan phase II S 1996.pdf
S7296-losartan phase II US 1996.pdf
S7298-Sumukadas 2007-ISRCTN676795.pdf
S730-FRIC (acute phase LMWH vs UFH) 1997.pdf
S7301-Cilazapril-Captopril Multi-centre Group (capt vs pbo) 1995.pdf
S7302-Cilazapril-Captopril Multi-centre Group (cila vs capt) 1995.pdf
S7304-WATCH (clopidogrel vs aspirin) 0.pdf
S7320-Walma (copie de 7319) 1997.pdf
S7321-Myers (copie de 7314) 1982.pdf
S7322-De jong (copie de 7312) 1994.pdf
S7323-Burr (copie de 7308) 1977.pdf
S733-TIMI 11 B (short term) 1998.pdf
S7330-RECORD 1 2008-NCT00329628.pdf
S7331-RECORD 2 2008-NCT00332020.pdf
S7332-RECORD 3 2008-NCT00361894.pdf
S7333-RECORD 4 2009-NCT00362232.pdf
S7334-FUSION 2 2008-NCT00091520.pdf
S7335-EVEREST 2008-NCT00071331.pdf
S7337-ASCEND-HF 2011-NCT00475852.pdf
S7346-GISSI-HF rosuvastatine 2008-NCT00336336.pdf
S7352-VERITAS I 2006-NCT00525707.pdf
S7353-VERITAS II 2007-NCT00525707.pdf
S7357-Ghose (vs placebo) 1993.pdf
S7358-Ghose (vs captopril) 1993.pdf
S7359-VHeFT I (prazosin) 1986.pdf
S7371-Horizons 2008-NCT00433966.pdf
S7373-DCCT (secondary prevention of retinopathy) 1993.pdf
S7377-Kumamoto (primary prev) 1995.pdf
S7382-Kumamoto (secondary prev) 1995.pdf
S7385-Lauritzen (STENO 1) 1991.pdf
S7386-Lauritzen (STENO 2) à effacer 1992.pdf
S7390-Post CABG (sub group) 1999.pdf
S7392-GISSI P (sub group) 2000.pdf
S7393-LIPS (sub group) 2002.pdf
S7394-ALLHAT-LLT (sub group) 2002.pdf
S7395-ALERT (sub group) 2003.pdf
S7397-PROVE IT TIMI 22 (diabetic sub group) 2006.pdf
S7398-TNT (sub group) 2006.pdf
S7399-FIELD 2005-ISRCTN64783481.pdf
S7407-ARTEMIS (Cohen) 2006.pdf
S7411-Díaz de la Llera 2007.pdf
S7413-SIRTAX (small vessels subgroup) 2005.pdf
S7416-Korean Randomized Study 0.pdf
S7421-European multicentre study 1991.pdf
S7422-ACTSG (Hull) sub-group 1992.pdf
S7423-Prandoni sub-group 1992.pdf
S7427-COLOMBUS sub group 1997.pdf
S7431-Certoparin-Study Group sub group 1998.pdf
S7432-Merli sub group 2001.pdf
S7435-ASSENT-4 PCI (Van de Werf) 2006-NCT00168792.pdf
S7437-PRAGUE (Widimisky) 2000.pdf
S7440-GRACIA (Fernandez-Aviles,) 2004.pdf
S7441-On-Time (van’t Hof) 2004.pdf
S7443-ERAMI (Mesquita Gabriel) 2003.pdf
S7444-REOMOBILE (Arntz) 2003.pdf
S7447-ReoPro-BRIDGING (Gyongyosi) 2004.pdf
S7448-INTAMI (Zeymer) 2005.pdf
S7451-BRAVE (Kastrati) 2004.pdf
S7452-FINESSE (combination-facilitated PCI) 2008-NCT00046228.pdf
S7459-ANDROMEDA 2008-NCT00543699.pdf
S7460-Schmitz-Huebner 1984.pdf
S7462-Kakkar and Murray 1985.pdf
S749-HINT (nifedipine vs metoprolol) 1988.pdf
S7498-Hoffmann and Largiader 1992.pdf
S750-Göbel (Dutch study) 1995.pdf
S7503-Gazzaniga (ISG) 1993.pdf
S7507-McLeod (Canadian) 1995.pdf
S7517-Warwick à exclure 2002.pdf
S7521-Navarro-Quilis A 2003.pdf
S7522-FX140, Simonneau G 2006.pdf
S7532-Senaran importé 2006.pdf
S754-No trial available for Other diuretics 0.pdf
S755-VHeFT I (hydralazine ISDN) 1986.pdf
S7550-Muiticentre 53,S4 1984.pdf
S7568-Kruse-Blinkenberg 1980.pdf
S7605-Goldhaber (tPA alone) 1990.pdf
S7609-Schweizer (local tPA) 2000.pdf
S761-HELAS (warfarin vs aspirin) 2006.pdf
S7612-Verhaeghe (high dose) 1989.pdf
S7613-Goldhaber (tPA+heparin) 1990.pdf
S7614-Schweizer (urokinase) 1998.pdf
S7615-Verhaeghe (low dose) 1989.pdf
S7616-Kakkar (streptokinase) 1969.pdf
S7618-Schweizer (local urokinase) 2000.pdf
S7619-Schweizer (systemic SK) 2000.pdf
S7620-Schweizer (systemic urokinase) 2000.pdf
S7630-APOLLO (Turpie) 2007.pdf
S7650-Schulman (subgroup) 2003.pdf
S7651-Wells (subgroup) 2005.pdf
S7654-Schulman 3 vs 1.5 1985 .pdf
S7655-Schulman 6 vs 3 1985 .pdf
S7657-British Thoracic Society 1992 .pdf
S7665-PREVENT (Ridker) 2003.pdf
S7679-SCD-HeFT (ICD vs placebo) 2005-NCT00000609.pdf
S7680-COMPANION (CRT+ICD vs MT) 2004.pdf
S7681-COMPANION (CRT+ICD vs CRT) 2004.pdf
S7683-AVID 1997-NCT00000531.pdf
S7687-CABG-patch 1997-NCT00000540.pdf
S7691-SCD-HeFT (ICD vs amiodarone) 2005-NCT00000609.pdf
S7695-Leclercq (Doublon CR-RD) 2003.pdf
S7698-Andreozzi (200 vs 100) 1996.pdf
S7703-Belcaro (LMWH vs low dose hep) 1999.pdf
S7716-Nocker (diclofenac) 1991.pdf
S7719-Stenox (enoxaparin 40mg) 2003.pdf
S7720-Titon (nadroparin 0.6ml vs naproxen) 1994.pdf
S7728-Merli (once daily vs UFH) 2001.pdf
S7734-AFFIRM 2002-NCT00000556.pdf
S7736-AF-CHF 2002-NCT00597077.pdf
S7737-AFFIRM Substudy (amiodarone vs sotalol) 2003.pdf
S7741-Bellandi (propafenone vs placebo) 2001.pdf
S7744-Carunchio (flecainide vs placebo) 1995.pdf
S7749-EURIDIS ADONIS (pooled analysis) 2009.pdf
S7757-Kochiadakis (amiodarone vs placebo) 2000.pdf
S7759-Kochiadakis b (propafenone vs placebo) 2004.pdf
S7761-Lloyd (quinidine vs placebo) 1984.pdf
S7764-PAFAC (quinidine vs placebo) 2004.pdf
S7770-SAFE-T (amiodarone vs placebo) 2005.pdf
S7774-SOPAT (quinidine vs placebo) 2004.pdf
S7777-Steinbeck (quinidine vs digoxin) 1988.pdf
S7783-AFFIRM Substudy (amiodarone vs class I drugs) 2003.pdf
S7784-Bellandi (sotalol vs placebo) 2001.pdf
S7785-Carunchio (sotalol vs placebo) 1995.pdf
S7786-Kochiadakis (sotalol vs placebo) 2000.pdf
S7787-Kochiadakis b (sotalol vs placebo) 2004.pdf
S7788-Lloyd (Disopyramide vs placebo) 1984.pdf
S7789-PAFAC (sotalol vs placebo) 2004.pdf
S7790-SAFE-T (sotalol vs placebo) 2005.pdf
S7791-SOPAT (sotalol vs placebo) 2004.pdf
S7792-Steinbeck (flecainide vs digoxin) 1988.pdf
S7794-Lloyd (Disopyramide vs quinidine) 1984.pdf
S7795-Steinbeck (quinidine vs flecainide) 1988.pdf
S7796-Lloyd (quinidine vs disopyramide) 1984.pdf
S7797-PAFAC (quinidine vs sotalol) 2004.pdf
S7798-SOPAT (quinidine vs sotalol) 2004.pdf
S7799-Kochiadakis (amiodarone vs sotalol) 2000.pdf
S7800-SAFE-T (amiodarone vs sotalol) 2005.pdf
S7801-Carunchio (sotalol vs flecianide) 1995.pdf
S7802-Kochiadakis b (sotalol vs propafenome) 2004.pdf
S7803-AFFIRM Substudy (sotalol vs class I drugs) 2003.pdf
S7838-St Thomas’ Trial 1983.pdf
S7856-MOST 2002-NCT00000561.pdf
S7864-Saner and Fricker 3000.pdf
S7874-RECORD 2009-NCT00379769.pdf
S7882-BEST (elderly subgroup) 2001.pdf
S7883-Carvedilol U.S. Trials (elderly subgroup) 1996.pdf
S7884-CIBIS II (elderly subgroup) 1999.pdf
S7885-COPERNICUS (elderly subgroup) 2001.pdf
S7886-MERIT-HF (elderly subgroup) 1999.pdf
S7900-Change of Heart 1999.pdf
S7907-HDFP 1979-NCT00000498.pdf
S792-BEST 2001-NCT00000560.pdf
S7920-Oslo Diet Exercise 0.pdf
S7922-Stamler 1989-NCT00000495.pdf
S793-CARMEN (carvedilol alone) 2004.pdf
S7932-Helsinki Businessmen Study 1985.pdf
S7933-CASCADE 2009-NCT00228423.pdf
S7939-Belcaro (coumadin vs low dose hep) 1999.pdf
S7940-Belcaro (ligation vs low dose hep) 1999.pdf
S7941-Belcaro (complete stripping vs low dose hep) 1999.pdf
S7943-STENOX (tenoxicam vs PBO) 2003.pdf
S7944-Katzenschlager (LMWH vs hep spraygel) 2003.pdf
S7945-Gorski (LMWH vs hep spraygel) 2005.pdf
S7946-STENOX (enox fixed dose vs NSAIDS) 2003.pdf
S7947-STENOX (prophylactic LMWH vs NSAIDs) 2003.pdf
S7948-Belcaro (prophylactic UFH vs no) 1999.pdf
S7949-Belcaro (hep vs no hep) 1989.pdf
S7950-Belcaro (hep vs defibrotide) 1990.pdf
S7951-Nocker (exhirud) 1991.pdf
S7952-Andreozzi (desmin SC vs 100) 1996.pdf
S7965-DURAC (Schulman) 1997.pdf
S798-Thrombosis Prevention trial (Warfarin) 1998-NCT00000614.pdf
S7984-SIRTAX diabetics 2005-NCT00297661.pdf
S7987-SIRIUS UA substudy 2007.pdf
S7996-WACS vitamin C 2007-NCT00000541.pdf
S800-Thrombosis Prevention trial (W plus A) 1998-NCT00000614.pdf
S8001-Austin (Abergavenny) 2008.pdf
S8002-UKPDS (vs SU or INS) 0.pdf
S8004-DeFronzo (vs glyburide) 1995.pdf
S8005-Horton (vs PBO) 2000.pdf
S8006-Hallsten (vs PBO) 2002.pdf
S8008-DeFronzo (vs PBO) 1995.pdf
S8009-Horton (vs Nateglinide) 2000.pdf
S8010-UKPDS (vs insulin) 0.pdf
S8011-UKPDS (vs chlorpropamide) 0.pdf
S8012-UKPDS (vs glibenclamide) 0.pdf
S8017-Nielsen importé 1994.pdf
S8019-CLARITY-TIMI 28 hors sujet 2005.pdf
S8024-CARS (warafrin 3mg) 1997.pdf
S8026-CARS (warfarin 1mg) 1997.pdf
S8027-ASPECT-2 (coumadin+ASA vs ASA) 2002.pdf
S8028-WARIS II (warfarin+ASA) 2002.pdf
S8051-MAGIC 2000-NCT00000610.pdf
S808-MITI 1993-NCT00000468.pdf
S8083-Centre Illinois 1993.pdf
S8087-TIMI-1 1987-NCT00000505.pdf
S8093-EMERAS (all delay) 1993.pdf
S8095-REACT (rescue PCI) 2005.pdf
S8101-REACT (repeat fibrinolysis) 2005.pdf
S8117-VA Neurology Section 1974.pdf
S8119-Frick à effacer DOUBLON 1993.pdf
S8125-HARP 1994-NCT00000461.pdf
S8127-POSCH 1990-NCT00000490.pdf
S8128-SCRIP 1994-NCT00000508.pdf
S8129-FATS Fukosawa (probucol) 2002.pdf
S8135-VA Neurology Section (estrogen) 1966.pdf
S8138-CDP estrogen 2.5 1975.pdf
S8139-VA drugs (Estrogen or thyroxine) 1968.pdf
S8175-HHS (Frick)(secondary prev subgroup) 1993.pdf
S8178-STARS (cholestyramine) 1992.pdf
S8192-STARS (St Thomas, diet) 1992.pdf
S8193-Los Angeles VA (Dayton) 1969.pdf
S8202-Finnish Mental Hospital (Miettinen) 1985.pdf
S8203-WHO Collaborative 1986.pdf
S8204-Göteborg (Wilhelmsen) 1986.pdf
S8209-CARE (subgroup) 1998.pdf
S8210-LIPID (sub group) 2001.pdf
S8212-PLAC I (sub group) 1995.pdf
S8213-REGRESS (subgroup) 1995.pdf
S8214-FLARE (subgroup) 1999.pdf
S8215-LIPS (subgroup) 2002.pdf
S8216-PROSPER (subgroup) 2002.pdf
S8217-CRISP 40mg 1994-NCT00000477.pdf
S8222-FEMINA (Dunselman) 1997.pdf
S8226-ATLANTIC (Burkhoff) 1999.pdf
S8229-Jones (doublons Frazier) 1999.pdf
S8239-Leon (high dose) 2005.pdf
S8255-Sixty Plus reinfarction Study 1980.pdf
S8257-German-Austrian Study Group (oac vs asp) 1980.pdf
S8258-OASIS pilot phase 2 0.pdf
S8289-PRACTICAL (captopril) 1994.pdf
S8316-Kostuk and Beanlands 0.pdf
S8326-Singh and Kocot 1976.pdf
S8329-Koster and Dunning 1985.pdf
S8351-Gonzalez-Fajardo 1999.pdf
S8368-STARS (vs coumadin+asp) 1998.pdf
S8369-STARS (vs aspirin) 1998.pdf
S8382-White (ticlopidine) 1991.pdf
S8383-M-HEART II (sulotroban) 1995.pdf
S8384-HORIZONS-AMI (Stone) 2008-NCT00433966.pdf
S8385-HORIZONS-AMI (Stone) doublons à effacer 2008.pdf
S8386-ACUITY (sub groups, bivalirudin alone) 2007.pdf
S8387-ACUITY (Stone) (bivalirudin alone) 2006-NCT00093158.pdf
S8389-CACHET (without abciximab) 2002.pdf
S8396-HPS (sub groups) 2004.pdf
S8402-ONTARGET (association vs telmisartan) 2008-NCT00153101.pdf
S8404-Bermudez-HT (normotensive) 1995.pdf
S8405-Bermudez-NT (hypertensive) 1995.pdf
S8414-ETTIC (Hanania) 2002.pdf
S8425-TRIMPOL II (Szwed) 2001.pdf
S8427-ATHENA 2009-NCT00174785.pdf
S8428-DIONISOS 2007-NCT00489736.pdf
S8430-ENOXACAN II (Bergqvist) 2002.pdf
S8431-FAME (Rasmussen) 2006.pdf
S8442-Turpie (GCS vs crtl) 1989.pdf
S8445-Wille-Jorgensen 1991.pdf
S8446-Wille-Jorgensen 1985.pdf
S8448-Scurr (GCS+IPC vs IPC) 1987.pdf
S8485-Dudek b (enox alone) 2000.pdf
S8487-Natarajan (without antiGp2b3a) 2003.pdf
S8488-Dubek b (+abciximal) 2001.pdf
S8489-Natarajan (+ antiGp2b3a) 2003.pdf
S8526-ACUITY (sub groups, bivalirudin +aGP2b3a) 2007.pdf
S8533-BACASS (Hoffman) 2006.pdf
S8536-Kentucky B (Brooks) 2004.pdf
S8538-SAPPHIRE (yadav) 2004.pdf
S8539-TESCAS-C (Ling) 2006.pdf
S8540-ACST-2 0-NCT00883402.pdf
S8543-CREST 2010-NCT00004732.pdf
S8544-ICSS 2010-ISRCTN25337470.pdf
S8546-TACTICS-TIMI 18 elderly (sub group) 2001.pdf
S8548-NQWMI (Eisenberg) 2005.pdf
S8551-ATACS (pilot study) (warfarin vs control) 1990.pdf
S8555-OASIS Pilot (phase 1) 1998.pdf
S8556-OASIS Pilot (phase 2) 1998.pdf
S8558-OASIS-2 Warfarin Substudy 2001.pdf
S8559-ASPECT-2 (coumadin+asp vs asp) 2002.pdf
S8565-Canadian (Aspirin vs PBO) 1985.pdf
S8566-Canadian (sulfinpyrazone alone) 1985.pdf
S8567-Theroux (heparin+ASP vs ASP) 1988.pdf
S8568-RISC (ASP+ heparin vs PBO) 1990.pdf
S8569-FRAXIS (14 days) 1998.pdf
S8570-TIMI 11 B (long term) 1998.pdf
S8571-FRISC (short term) 1996.pdf
S8573-TRITON-TIMI 38 2007-NCT00097591.pdf
S8574-TRITON-TIMI 38 2007-NCT00097591.pdf
S8579-Huynh (warfarin vs aspirin) 2001.pdf
S8580-ASPECT-2 (coumadin vs aspirin) 2002.pdf
S8581-ATACS (pilot study) warfarin vs aspirin 1990.pdf
S8582-LoWASA (copie de 8025) 0.pdf
S8583-German-Austrian Study Group (oac vs pbo) 1980.pdf
S8585-ADVANCE-1 2008-NCT00371683.pdf
S8586-APPRAISE-1 (10mg od) 2009-NCT00313300.pdf
S8589-ACUITY (biva alone vs hep+aGP2b3a) 2006-NCT00093158.pdf
S8590-ACUITY (biva+aGP2b3a vs hep+aGP2b3a) 2006-NCT00093158.pdf
S8591-ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé 2007.pdf
S8592-ACUITY (sub groups PCI, bivalirudin alone) importé 2007.pdf
S8594-BEAUTIFUL 2008-NCT00143507.pdf
S8595-TRANSCEND 2008-NCT00153101.pdf
S8596-GISSI HF fatty acid 2008-NCT00336336..pdf
S8601-VA CARDS 0-NCT00326196.pdf
S8602-PIHRATE 0-NCT00377650.pdf
S8603-TAPAS 2008-ISRCTN16716833.pdf
S8607-CAST I 1991-NCT00000526.pdf
S8608-CAST II (early treatment) 1992.pdf
S8614-APPRAISE-1 (2.5 mg bid) 2009-NCT00313300 .pdf
S8616-TRANSFER-AMI 2008-NCT00164190.pdf
S8621-SPEED (Phase A) 2000.pdf
S8624-UKPDS Sulfonyurea–insulin 10 year 2008-ISRCTN75451837.pdf
S8626-UKPDS Metformin10 year 2008-ISRCTN75451837.pdf
S8627-UKPDS 38 10 years 2008-ISRCTN75451837.pdf
S8630-TAxi (diabetics) 3000.pdf
S8631-REALITY (diabetics) 2006.pdf
S8632-SIRIUS (diabetics) 2003.pdf
S8633-ISAR-test (diabetics) 2006.pdf
S8635-ISAR-DESIRE (SES vs PTCA) 2005.pdf
S8636-ISAR-DESIRE (PES vs PTCA) 2005.pdf
S8639-TAXUS V ISR 2006-NCT00287573.pdf
S8658-DEDICATION 2008-NCT00192868.pdf
S8659-Cohen (copie de 7407) 2006.pdf
S8660-Cohen (30 mg) à effacer 2006.pdf
S8662-BARI 2D 2009-NCT00006305.pdf
S8663-TAXUS V small vessels sub groups 0.pdf
S8664-CARDIA (DES subgroups) 0.pdf
S8665-LEMANS 2002-NCT00375063.pdf
S8669-HORIZONS-AMI Stent 2008.pdf
S8670-ZEST AMI (vs SES) 2009-NCT00422565.pdf
S8671-FAME 2008-NCT00267774.pdf
S8772-CAST II (late treatment) 1992.pdf
S8773-ISAR TEST 2 (vs SES) 2009-NCT00332397.pdf
S8774-ISAR TEST 2 (vs ZES) 2009-NCT00332397.pdf
S8775-SORT-OUT-3 2010-NCT00660478.pdf
S8781-ASCEND (aspirin) 0-NCT00135226.pdf
S8782-POPADAD aspirin 2008-ISRCTN53295293.pdf
S8784-SOS 2008-NCT00247208.pdf
S8805-Einstein-DVT Dose-Ranging Study 2008.pdf
S8809-HF-ACTION 2008-NCT00047437.pdf
S8811-PHS II vitamin C 2008-NCT00270647.pdf
S8812-PHS II beta carotene 2003-NCT00270647.pdf
S8813-WAFACS 2008-NCT00000541.pdf
S8814-WACS vitamin E 2007-NCT00000541.pdf
S8816-WACS beta-caroten 2007-NCT00000541.pdf
S8820-APPROACH 2008-NCT00116831.pdf
S8822-JPAD DOUBLON à effacer 2008-NCT00110448.pdf
S8829-PHS II vitamin E 2008-NCT00270647.pdf
S8830-ACCEPT-D 0-ISRCTN48110081.pdf
S8835-Apenstrom and Korsan-Bengtsen 1964.pdf
S8842-Sixty Plus Reinfarction 1980.pdf
S8846-Drapkin and Merskey 1972.pdf
S8848-CHARM preserved 2003.pdf
S8849-TOPCAT 0-NCT00094302.pdf
S8850-Barzizza (warfarin) 1993.pdf
S8853-TIMACS 2009-NCT00552513.pdf
S8854-JPAD 2008-NCT00110448.pdf
S8855-SEARCH 2010-NCT00124072.pdf
S8856-HOPE-2 (Lonn) 2006-NCT00106886.pdf
S8858-WENBIT (folic ac,B12,B6) 2008-NCT00354081.pdf
S8863-CASSIS (enalapril) 1995.pdf
S8864-CASSIS (spirapril) 1995.pdf
S8866-International Study Group (Lewis) 1989.pdf
S8867-NETWORK (2.5 bid vs 10 bid) 1998.pdf
S8870-NETWORK (5 bid vs 10 bid) 1998.pdf
S8885-A4 (Jais) 2008-NCT00540787.pdf
S8901-SANDS 2008-NCT00047424.pdf
S8904-TROICA 2008-NCT00157261.pdf
S8908-VADT 2008-NCT00032487.pdf
S8911-FAST Fukuoka pravastatin 2002.pdf
S8924-Udelson 2008-NCT00132886.pdf
S8927-COSTAR II diabetic (sub group) 2008.pdf
S8928-Botticelli DVT 2008-NCT00252005.pdf
S8929-González-Fajardo 2008.pdf
S8941-TIMI II-A (defered) 0.pdf
S8942-TAMI-5 (Califf) 1991.pdf
S8943-SHOCK (Hochman) 1999-NCT00000552.pdf
S8948-SPEED (GUSTO-4 pilot) Hermann 2000.pdf
S8949-Kurihara à effacer 2004.pdf
S8951-combined TIMI 10B–TIMI 14 (Schweiger) 2001.pdf
S8957-MERLIN (Sutton) 2004.pdf
S8972-SWISSI II 2007-NCT00387231.pdf
S8976-CADILLAC abciximab. 2002.pdf
S8977-CADILLAC (no abciximab) 2002.pdf
S8985-ECSS (European) 1988.pdf
S8986-CASS 1983-NCT00000489.pdf
S8991-Coronary Artery Bypass Graft Surgery Trialists Collaboration 1994.pdf
S8992-CABG Trialists Collaboration - one vessel subgroups 1994.pdf
S8993-CABG Trialists Collaboration - two vessels subgroups 1994.pdf
S8994-CABG Trialists Collaboration - three vessels subgroups 1994.pdf
S8995-CABG Trialists Collaboration -left main artery subgroups 1994.pdf
S8996-CABG Trialists Collaboration - normal LV function subgroups 1994.pdf
S8997-CABG Trialists Collaboration -abnormal LV function subgroups 1994.pdf
S9010-MAASTRICHT (Vermeer) 1999.pdf
S9016-PRAGUE-1 (thrombolysis+PTCA) 2000.pdf
S9037-TAMI 5 (t-PA vs uroK) 1991.pdf
S9043-TAMI 5 (t-PA+uroK vs tPA) 1991.pdf
S9051-Leon (low dose) 2005.pdf
S9069-DEAR-MI 2006-NCT00257153.pdf
S9080-Export (Chevalier) 2008.pdf
S9124-VanGogh DVT 2007-NCT00067093.pdf
S9125-VanGogh extension 2007-NCT00071279.pdf
S9127-HEAAL 2009-NCT00090259.pdf
S9130-TITAX AMI 2009-NCT00495664.pdf
S9134-ISAR TEST 3 (BP) 2009.pdf
S9135-PROPHESS 2008-NCT00153062.pdf
S9146-GISSI Prevenzione 2000.pdf
S9147-HHS (sub group) 1987.pdf
S9149-VA-HIT (sub group) 1999.pdf
S9156-ISAR TEST 3 (PF) 2009.pdf
S9158-BARI 2D à effacer -NCT00006305.pdf
S9160-London diabetes 1983.pdf
S9175-DAVID II 2009-NCT00187187.pdf
S9224-TRA-PCI 2009-NCT00132912.pdf
S9316-Takahashi et al 2006.pdf
S9320-Tepel et al 2008-NCT00124969.pdf
S9321-Han 2009-NCT00404716.pdf
S9323-ZEST (vs PES) 2009-NCT00418067.pdf
S9325-STICH (ventricular reconstruction) 2009-NCT00023595.pdf
S9327-NAPLES II (Briguori) 2009.pdf
S9329-ABOARD 2009-NCT00442949.pdf
S9331-OMEGA 2009-NCT00251134.pdf
S9345-ACTIVE A 2009-NCT00249873.pdf
S9353-DIAD 2009-NCT00769275.pdf
S9354-DYNAMIT 2010-NCT00627783.pdf
S9355-GISSI-AF (Disertori) 2009-NCT00376272.pdf
S9357-CAPTIVATE 2009-NCT00151788.pdf
S9358-ACCELERATE 2017-NCT01687998.pdf
S9360-RADIANCE 1 2007-NCT00136981.pdf
S9361-ACTIVATE 2006-NCT00185042.pdf
S9362-ILLUMINATE 2007-NCT00134264.pdf
S9364-ILLUSTRATE 2007-NCT00134173.pdf
S9365-Kastelein à effacer 2007-NCT00136981.pdf
S9385-POST CABG 0-NCT00000463.pdf
S9388-PEPI 1995-NCT00000466.pdf
S9389-Becker 0-NCT00000486.pdf
S9391-MERCATOR 0-NCT00000496.pdf
S9394-NCT00000527 0-NCT00000527.pdf
S9396-ERA (estrogen alone ) 2000-NCT00000549.pdf
S9397-HATS à effacer doublon 0-NCT00000553.pdf
S9398-WAVE 2002-NCT00000555.pdf
S9399-WELL-HART (estrogen alone) 2003-NCT00000559.pdf
S9400-Schulman (NHLBI) (estrogen alone) 2002-NCT00000601.pdf
S9401-EAGAR 2006-NCT00000605.pdf
S9403-ESCAPE 0-NCT00000619.pdf
S9410-NCT00032370 0-NCT00032370.pdf
S9411-THINRS 0-NCT00032591.pdf
S9415-Cuenca 0-NCT00035451.pdf
S9416-Phillips 0-NCT00035464.pdf
S9418-NCT00040612 0-NCT00040612.pdf
S9419-VMAC (intravenous neseritide) 2002-NCT00083772.pdf
S9420-NSGET (comparative trial) 2000.pdf
S9421-FUSION 1 2004-NCT00270361.pdf
S9422-RECOVER -NCT00881777.pdf
S9424-Pre-RELAX-AHF 2009-NCT00520806.pdf
S9426-Ranucci 0-NCT00881192.pdf
S9428-PROTECT (fundaparinux) -NCT00881088.pdf
S9429-PROTECT (nadroparin) -NCT00881088.pdf
S9432-Schacky -NCT00886704.pdf
S9436-WARCEF 2012-NCT00041938.pdf
S9437-NCT00043628 0-NCT00043628.pdf
S9439-Udelson 2007-NCT00043758.pdf
S9444-REVIVE II 2013-NCT00048425.pdf
S9445-STAMINA-HeFT (Ghali) 2008-NCT00049985.pdf
S9446-ARISE 2008-NCT00066898.pdf
S9447-Meybohm -NCT00882622.pdf
S9452-Hausenloy 2007-NCT00397163.pdf
S9453-FREEDOM-C2 -NCT00887978.pdf
S9456-REMODEL -NCT00082589.pdf
S9457-Losordo 2007-NCT00081913.pdf
S9458-van Veldhuisen 2007-NCT00086086.pdf
S9460-AGENT-1 (Grines) 2002.pdf
S9461-AGENT-2 (Grines) 2003.pdf
S9462-AGENT-3 0-NCT00346437.pdf
S9463-AGENT-4 0-NCT00185263.pdf
S9465-AGENT 3 and 4 pooled 0.pdf
S9468-REVASC (Stewart) 2006.pdf
S9469-EUROINJECT-ONE (Gyöngyösi) 2005.pdf
S9470-ISAR-SAFE 2009-NCT00661206.pdf
S9472-JELIS 2009-NCT00231738.pdf
S9473-APEX-AMI 2007-NCT00091637.pdf
S9474-TRIUMPH 2007-NCT00112281.pdf
S9479-PRIMO-CABG -NCT00088179.pdf
S9480-Genzyme SMC00202 à effacer .pdf
S9481-Genzyme SMC00202 -NCT00102128.pdf
S9482-ANTIPAF -NCT00098137.pdf
S9484-IMMEDIATE -NCT00091507.pdf
S9485-SOFA transferé à effacer -NCT00110838.pdf
S9486-Raitt transféré à effacer 0-NCT00004558.pdf
S9488-Raitt 2006-NCT00004558.pdf
S9489-SOFA 2006-NCT00110838.pdf
S9492-NCT00090714 -NCT00090714.pdf
S9493-ExTRACT-TIMI25 2006-NCT00077792.pdf
S9494-EMPOWER -NCT00077948.pdf
S9496-EARLY ACS -NCT00089895.pdf
S9497-NCT00090259 -NCT00090259.pdf
S9498-RESOLVE-AF -NCT00111488.pdf
S9499-Schmieder (vs HCTZ) 2009.pdf
S9500-AVOID 2008-NCT00097955.pdf
S9503-ATMOSPHERE -NCT00853658.pdf
S9504-ACCLAIM 2008-NCT00111969.pdf
S9505-PROVIDENCE -NCT00116792.pdf
S9506-Ponikowski 2007-NCT00117234.pdf
S9508-REVIVAL-2 (Zohlnhöfer ) 2006-NCT00126100.pdf
S9510-G-CSF-STEMI (Engelmann) 2006.pdf
S9511-FIRSTLINE-AMI (Ince) 2005.pdf
S9512-MAGIC Cell-3-DES (Kang) 2006.pdf
S9513-MAGIC (G-CSF) (Kang) 2004.pdf
S9516-Ellis 2006-NCT00215124.pdf
S9518-RIGENERA (Leone) 2007.pdf
S9519-Suarez de Lezo (G-CSF) 2007.pdf
S9520-PAD (Hallstrom) 2004.pdf
S9523-BBS (Moller) 2010-NCT00120991.pdf
S9525-DOORS 2009-NCT00123981.pdf
S9527-Nouvel essai -NCT00125437.pdf
S9531-CAPRAF (Tveit) 2007-NCT00130975.pdf
S9533-RethinQ 2007-NCT00132977.pdf
S9534-MANTRA-PAF -NCT00133211.pdf
S9535-Jikei Heart DOUBLON 2007-NCT00133328.pdf
S9536-APRICOT-3 -NCT00138034.pdf
S9538-CAFCOAF (Stabile) 2006.pdf
S9541-senior PAMI 2005-NCT00136929.pdf
S9543-CRIT Pilot -NCT00126334.pdf
S9544-n3-PUFA-HF -NCT00149409.pdf
S9545-van Kraaij -NCT00149422.pdf
S9551-TRANSFER-AMI à effacer -NCT00164190.pdf
S9554-NORDISTEMI 2009-NCT00161005.pdf
S9556-RAPS (Desai) 2004-NCT00187356.pdf
S9557-RSVP 2008-NCT00139399.pdf
S9558-Czech trial -NCT00171275.pdf
S9559-Hayward (Younger) 2008.pdf
S9560-Gaudino (radial A) 2005.pdf
S9561-PRAGUE 4 (Widimsky) 2004.pdf
S9562-BHACAS I (Ascione) 1999.pdf
S9563-BHACAS II (Angelini) 2002.pdf
S9564-OCTOPUS (van Dijk) 2002.pdf
S9580-Legare 2004-NCT00216957.pdf
S9583-PRAGUE-4 DOUBLON 2004.pdf
S9589-Motallebzadeh b 2006.pdf
S9596-ROOBY (Shroyer) 2009-NCT00032630.pdf
S9598-CADUCEUS -NCT00893360.pdf
S9605-Jorgensen (NICOLE) 2001.pdf
S9678-ASTRONAUT 2013-NCT00894387.pdf
S9683-ASSOCIATE - CL3-16257-057 DOUBLON -NCT00202566.pdf
S9688-ACTIVE I 2009-NCT00249795.pdf
S9689-EMPHASIS-HF 2010-NCT00232180.pdf
S9690-STOP-AF -NCT00252967.pdf
S9691-TRIANA 2009-NCT00257309.pdf
S9696-PLATO 2009-NCT00391872.pdf
S9697-DISPERSE-2 (90mg) 2007.pdf
S9698-CHAMPION-PLATFORM 2009-NCT00385138.pdf
S9699-CHAMPION-PCI 2009-NCT00305162.pdf
S9707-MAGIC (cell infusion ) 2004.pdf
S9708-Suarez de Lezo (cell) 2007.pdf
S9710-PROactive 2005-NCT00174993.pdf
S9714-MAGIC Cell-3-DES (Kang) 2006.pdf
S9723-REPAIR-AMI (Schachinger) 2006-NCT00279175.pdf
S9727-NEVO RES-ELUTION I 0-NCT00714883.pdf
S9729-TRIGGER-PCI -NCT00910299.pdf
S9737-PROTECT-TIMI 30 2006-NCT00250471.pdf
S9740-PRECEDENT 2002-NCT00270400.pdf
S9741-Ontario -NCT00259493.pdf
S9743-INTAMI 2005-NCT00251823.pdf
S9754-AIM-HIGH 2011-NCT00120289.pdf
S9755-HPS 2-Thrive -NCT00461630.pdf
S9758-Imperial College -NCT00285454.pdf
S9761-COREA TAXUS -NCT00292721.pdf
S9762-HERS 1998-NCT00319566.pdf
S9763-CARACCASS -NCT00317265.pdf
S9764-REGENT (Wojakowski) -NCT00316381.pdf
S9767-Thiele 2009-NCT00299429.pdf
S9768-ATLAS ACS-TIMI 46 (DOUBLONS) 2009-NCT00402597.pdf
S9774-MIRACL (sub-group) (Schwartz) 2004.pdf
S9787-REACT (rescue PCI vs repeat fibrinolysis) 2005.pdf
S9788-ASPEN (primary prevention sub group) 2006.pdf
S9789-HPS (diabetic primary prevention sub group) 2003.pdf
S9790-PROSPER (primary prevention subgroup) 2002.pdf
S9791-ARMYDA-3 (AF ancillary study) 2006.pdf
S9793-MIRACL (AF ancillary study) 2001.pdf
S9911-NCT00975234 -NCT00975234.pdf
S9912-RECOVER 2 2009-NCT00972270.pdf
S9973-COGENT 2009-NCT00557921.pdf
S9974-OCLA 2008-NCT00349661.pdf
S9976-COMPARE 2009-NCT01016041.pdf
S9977-Nordic-Baltic Bifurcation Study III 2009-NCT00914199.pdf
S9978-DEBATER (SES vs BMS) 2009.pdf
S9979-PAINT (sirolimus) 2009-NCT00752362.pdf
S9986-PAD DOUBLONS A EFFACER 2007.pdf
S9987-IRIS 2009-NCT00157768.pdf
S9991-WENBIT (folic ac,B12) 2008-NCT00354081.pdf
S9992-WENBIT (vit B6) 2008-NCT00354081.pdf
S9993-CARRPO 2009-NCT00159991.pdf
S9997-OVER 2009-NCT00094575.pdf
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
